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PART I Gene Expression Profiling of Chinese MM 
Multiple myeloma (MM) is a clonal plasma cell derived hematological 
malignancy with elusive oncogenesis. Although MM occurs more commonly in 
western populations, there is an upward trend for the incidence of MM among Asian 
regions, including Hong Kong. Increasing evidence suggests that genetic alterations 
play an important role in MM development. Yet, detailed studies in our locality are 
currently lacking. Therefore in this part, we aimed to elucidate the genetic 
abnormalities in MM by investigating altered gene expression in MM plasma cells 
using DNA microarray technology. 
In this study, bone marrow (BM) plasma cells from 12 Chinese MM patients at 
diagnosis and 3 Chinese healthy individuals were isolated by CD138 immunosorting 
and studied for gene expression profiling using DNA microarray with 45,674 human 
unique genes. With unsupervised Hierarchical Clustering and Principle Component 
Analysis (PCA), all MM samples were distinguished from normal samples based on 
their gene expression profiles. By supervised class comparison analysis using a 
combination of two-samples t-statistics and Significance Analysis of Microarrays 
(SAM), 311 genes were found to be differentially expressed between MM and 
normal plasma cells with statistical significance (p<0.001). They included 30 
upregulated and 281 downregulated genes in MM. Within these differentially 
expressed genes, genes involved in apoptosis, cell proliferation, cell cycle regulation, 
angiogenesis，cell migration and adhesion were identified. In addition, a number of 
MM-related and potential tumor suppressor genes were found differentially 
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expressed. The differential expression of four genes, SERF INF 1 {Serpin peptidase 
inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 
1% PINKJ {PTEN induced putative kinase), RJRAGD {Ras-related GTP binding D) 
and UNCI SB {Unc-13 homolog B), were verified by real-time quantitative PGR in a 
further series of 12 independent MM samples. 
PART n Development of MP Treatment Response Biomarker in MM 
Despite recent advances, melphalan and prednisone (MP) remains one of the 
major therapeutic options, alone or as part of the combination therapy, for newly 
diagnosed MM patients. However, only 50-60% patients respond to MP treatment. 
Unfortunately, MP non-responder status could only be confirmed after the patients 
have received multiple courses of toxic but ineffective chemotherapy. Thus, the 
purpose of this study is to identify biomarkers for predicting MP treatment response 
prior to decision on treatment option. 
Twelve MM patients clinically defined as good responders (GR, N=6) and poor 
responders (PR, N=6) to MP treatment were selected for this study. Plasma cells 
from their BM samples at diagnosis were isolated by CD 138 immunosorting for gene 
expression profiling using DNA microarray with 45,674 human unique genes. Eight 
out of 12 samples showed correct classification based on their gene expression 
profiles in unsupervised hierarchical clustering and PCA. Using supervised 
two-sample t-statistics and SAM, CYB5D1 {Cytochrome b5 domain containing 1) 
was the only gene differentially expressed in GR and PR, and its differential 
expression was validated by real-time quantitative RT-PCR (p=0.01). The positive 
predictive value (PPV) and negative predictive value (NPV) of low CYB5D1 gene 
expression in MP treatment response prediction were 100% and 66.7% respectively. 
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The 100% PPV highlighted the prognostic significance of low CYB5D1 in 
identifying GR to MP treatment. 
In conclusion, we successfully established the gene expression profiles of 
Chinese MM and demonstrated that MM plasma cells could be differentiated from 
normal plasma cells according to their gene expression profiles. The finding of 
differential expression of SERPINFJ, PINKl, RRAGD and UNCI SB support their 
potential roles in MM tumorigenesis. Last but not least, we identified and verified a 
single biomarker, CYB5D1’ for prediction of good MP treatment response and that 
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Chapter 1 Introduction 
Chapter 1 Introduction 
Multiple myeloma (MM) is a clonal plasma cell-derived malignancy that accounts for 
almost 10% of all hematologic malignancies. The development of MM is characterized 
by a multi-step process，from benign monoclonal gammopathy of undetermined 
significance (MGUS) through asymptomatic myeloma to the familiar entity of 
symptomatic MM. This biological process involves multiple genetic changes such as 
inactivation of tumor suppressor genes (Gonzalez et al, 2000) and activation of 
oncogenes (Fabris et al, 2005) that are driven by an ongoing genomic instability 
(Sawyer et al, 2005). However, the underlying mechanisms of MM pathogenesis remain 
largely unclear. MM also generally occurs more commonly in western populations, but 
there is an upward trend for the incidence of MM among westernized Asian regions, like 
Hong Kong (Parkin et al, 2001). Although genetic alterations played a very important 
role in MM development, global study of altered gene expression，in our locality has 
been lacking. 
In order to earn more knowledge in genetic changes during MM development in our 
region, we will investigate the global gene expression changes from non-malignant 
normal plasma cells to malignant MM plasma cells in Chinese. By means of DNA 
microarray, we will be able to establish the global gene expression profiles of Chinese 
MM and to identify potential genes related to MM development. This finding can help 
us to gain more insights into the molecular tumorigenesis of MM and ultimately, 
contribute to MM diagnosis, prognosis and identification of new targets for novel 
therapeutics development. 
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On the other hand, effective therapies with alkylating agents for MM patients started 
since the early 1960s (Rivers et al，1969). Despite intense efforts in the development of 
new drugs for the past four decades, melphalan remains one of the most common 
chemotheraptic agent used in MM patients. Typically, melphalan is given with 
prednisone (MP) for the patients. However，the response rate is only 50% to 60% 
(Anderson et al.，2000) and no current marker is able to predict patient's responsiveness 
to MP treatment. Clinically, the non-responders to MP have to go through the treatment 
and suffer from the toxic side effects before they are terminated from the ineffective 
treatment. Thus, it would be critically important to identify biomarkers to accurately 
predict the patient's treatment outcome prior to starting the chemotherapy, so that not 
only costs and the quality of life for those patients can be saved but more importantly, 
they can immediately receive other alternative therapies for better results. 
Recently, DNA microarray has been successfully utilized as a tool for predicting 
chemosensitivity before treatments in various cancers by identifying sets of genes that 
their expression correlated with drug sensitivity as response prediction markers 
(Parissenti et al., 2007). Based on the hypothesis that distinctive transcriptional patterns 
are associated with MP responders and non-responders and utilization of their molecular 
signatures can predict the patient's outcomes in response to the treatments, we will 
determine the gene expression profiles of MM plasma cells in both responders and 
non-responders to MP at diagnosis by DNA microarray, from which the molecular 
signatures of MP responders and non-responders can be identified. This enables us to 
improve MM treatment by early identification of MP non-responders before the 
commencement of chemotherapy, with a more effective and personalized therapy. 
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2.1. Multiple Myeloma (MM) 
MM is a clonal plasma cell-derived hematologic malignancy characterized by 
uncontrolled proliferation of monoclonal plasma cells. These cells accumulate in the 
bone marrow and secret monoclonal immunoglobulins and cytokines, which cause 
decreased bone marrow function and destruction of bone tissue. Patients with MM 
usually present with bone pain related to lytic bone lesions, frequent anaemia and renal 
impairment. 
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Fig 2.1 A smear of bone marrow aspirate from a patient with MM 
Note that there are numerous plasma cells with eccentric nuclei and a perinuclear halo of 
clearer cytoplasm. 
(Adopted from website: www.md.huji.ac.il) 
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2.1.1 Epidemiology 
MM accounts for approximately 1% of all cancer and is the second most prevalent 
hematologic malignancy, at about 10%，after non-Hodgkin's lymphoma. 
According to Surveillance Epidemiology and End Results Cancer Statistics Review of 
National Cancer Institute (SEER CSR, 1975-2003), the age-adjusted incidence rate of 
MM was 5.5 per 100,000 persons per year with higher rates in men (6.9 per 100,000 
men) than women (4.5 per 100,000 women). The age-adjusted death rate was 3.8 per 
100,000 men and women per year and the overall 5-year relative survival rate was only 
about 32%. The median age at diagnosis for MM was 70 years of age, with less than 5 % 
of cases were diagnosed in people under the age of 45. Rates of incidence and mortality 
were found consistently highest in African and lowest in Asian population relative to 
Caucasians. Globally, the incidence of MM is high in North America, Australia/ New 
Zealand, Northern Europe, and Western Europe compared with Asian countries, with a 
slow increase in both the incidence and mortality in most regions of the world (Parkin et 
al； 2005). Hong Kong has the second highest incidence rate of MM after Japan among 
the Eastern and Southeast Asian countries or regions (Parkin et al” 2001). 
In Hong Kong, according to the statistics from Hong Kong Cancer Registry of Hospital 
Authority in 2004, the incidence rate of MM was 1.9 per 100,000 persons with 179 new 
cases diagnosed. The ratio of MM incidence in men and women was 1.45:1 and the 
median age at presentation was 74. 99 deaths were reported, accounting for around 1% 
of all cancer deaths in Hong Kong. 
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2.1.2 Cause and Risk Factors 
The exact etiology of MM remains unclear. Occasionally it is possible to identify 
members of the same family with MM, although no evidence suggests a hereditary basis 
for the disease. Environmental factors such as toxic chemical and radiation exposure 
have been associated with an increased risk in developing MM (George and Sadovsky, 
1999). Prolonged exposure of pesticides or herbicides such as DDT and chronic 
antigenic stimulation was suggested to be risk factors for MM (Angtuaco et al, 2004; 
Zaidi and Vesole，2001). On the other hand, preliminary research has implicated several 
viruses such as human immunodeficiency virus (HIV), hepatitis, herpes virus type 8 in 
the etiology of MM (Flaitz and Hicks, 1998). 
2.1.3 Pathophysiology 
Mature plasma cells normally make up less than 5 % of bone marrow cells. Their 
precursors are B lymphocytes that migrate to the bone marrow from the lymph nodes in 
response to antigen stimulation and cytokines released from helper T cells in the lymph 
node. In the bone marrow, the precursor cells stop proliferation and differentiate into 
mature immuloglobulin-producing plasma cells, which are responsible for humoral 
immunity. Five classes of immunoglobulins (IgG, IgA, IgM, IgD，and IgE) are secreted 
by plasma cells when exposed to foreign antigens (Devenney and Erickson, 2004). 
MM is a clonal proliferation of neoplastic plasma cells which differ from normal plasma 
cells in development and function. These neoplastic cells are often immature and may 
have the appearance of plasmablasts. They produce and secrete excess monoclonal 
immunoglobulins (M protein) which are mostly IgG (55 %) or IgA or (26 %). Myelomas 
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that are nonsecretory or secrete IgM, IgD，and IgE，are rare (Devenney and Erickson, 
2004). 
2.1.4 Diagnosis and Clinical Presentation 
As the clinical presentation of MM varies in different patients, three hallmark features 
are used in the diagnosis of MM. One is the accumulation of clonal plasma cells in bone 
marrow, making up more than 10% bone marrow cells. Another is secretion of M protein 
as paraproteins in serum and or urine. The third one is the formation of bone lesions. 
Besides, part of MM patients may suffer from anemia, kidney failure, bone pain, 
pathological fracture, thrombocytopenia, hepercalcemia, elevated creatinine, recurrent 
infection (Devenney and Erickson, 2004). 
2.1.5 Classification of Plasma Cell Disorders 
Myeloma can be classified into four categories so as to determine when and how a 
patient should be treated. The development of myeloma goes through the spectrum from 
benign monoclonal gammopathy through asymptomatic MM and then indolent MM and 
to the familiar entity of symptomatic MM. Their characteristics are described in Table 
2.1. 
2.1.5.1 Monoclonal Gammopathy of Undetermined Significance (MGUS) 
MGUS is an asymptomatic clinical state with the presence of a stable，low level of M 
proteins in the serum or urine of persons with less than 10% plasma cells ion the bone 
marrow and no evidence of MM, amyloidosis, Waldenstrom's macroglobulinaemia or 
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related disorder (Kuehl and Bergsagel, 2002). It is present in 1% adults over the age of 
25 and 3% of the population over the age of 50. 
MGUS is considered as the precursor of MM as one-third of MM had a preceding 
history of MGUS with a progression rate of 1% per year from MGUS to MM 
(Hideshima et a/.，2004). However, standard clinical features cannot predict whether 
individuals with MGUS will develop into MM or remain in stable condition, therefore 
patients with MGUS are only monitored and treated unless the disease progresses to a 
malignant condition. 
2.1.5.2 Asymptomatic (Smouldering) MM 
Patients with symptomatic MM has a stable plasma cell content of greater than 10% in 
the bone marrow (intramedullary site) with no anaemia, renal insufficiency, or skeletal 
lesions (Kuehl and Bergsagel, 2002). They may have small amounts of M protein in 
urine and decreased amount of normal immunoglobulin in serum, but the plasma cell 
labeling index is low (Kyle and Greipp, 1980). These patients are biologically similar to 
those with MGUS, but they are followed up closely as large proportion of them would 
progress to symptomatic MM with a progression rate to malignant MM of 10-20% per 
year. Asymptomatic MM accounts for approximately 15% of all cases with newly 
diagnosed MM (Rajkumar et al, 2007). 
2.1.5.3 Indolent MM 
Patients with indolent MM are very similar to those with asymptomatic MM. They have 
M protein and increased number of plasma cells in bone marrow, and may also have 
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mild anemia or a few bone lesions. These patients are monitored regularly and are 
treated if disease progresses. 
2.1.5.4 Symptomatic MM 
Patients with Symptomatic MM are characterized by overproduction of M protein and 
increased number of plasma cells (>30% plasma cell content) in bone marrow. They also 
have anemia, kidney failure and hypercalcemia or numerous lytic bone lesions. These 
patients are subjected to immediate treatment. 
Table 2.1 Classification and characteristics of MGUS and MM 
Classification Characteristics 
MGUS 
> Serum monoclonal immunoglobulin < 3 g/dL 
> Bone marrow plasma cells < 1 0 % 
> Absence of anemia, renal failure, hypercalcemia, lytic bone 
lesions 
Asymptomatic MM 
> Serum monoclonal immunoglobulin > 3 g/dL 
> and/or bone marrow plasma cells > 1 0 % 
> Absence of anemia，renal failure, hypercalcemia, lytic 
bone lesions 
Indolent MM 
> Stable serum/urine monoclonal immunoglobulin 
> Bone marrow plasmacytosis 
> Mild anemia or few small lytic bone lesions 
> Absence of symptoms 
Symptomatic MM 
> Presence of serum/urine monoclonal immunoglobulin 
> Bone marrow plasmacytosis (>30 %) 
> Anemia, renal failure, hypercalcemia, lytic bone lesions 
(Adopted from Mutliplte Myeloma Research Foundation, Website: http://www.multiplemyeloma.Org/about_myeloma/2.05.html) 
8 
Chapter 2 Literature Review 
2.1.6 Staging 
There are two MM staging systems, the Durie-Salmon system and the international 
staging system. 
The Durie-Salmon system has been most widely accepted since 1975 (Dune and Salmon, 
1975) (Table 2.2), in which clinical stage of disease (stage I，II，or III) is based on four 
measurements: levels of M protein，serum haemoglobin levels, serum calcium levels and 
the number of lytic bone lesions. Each stage is further subdivided into two subgroups A 
and B by the renal function determined by the serum creatinine levels. 
A new, simpler, more cost-effective alternative is the International Staging System (ISS) 
(Greipp et al, 2005) (Table 2.3). The ISS is based on the assessment of two blood test 
results, beta 2-microglobulin (P2-M) and albumin, which together showed the greatest 
prognostic power for MM. This system has only recently been developed，but has 
already been proven more sensitive in discriminating between three stages of the disease, 
which indicate different levels of projected survival and suggest increasingly more 
aggressive treatment strategies. 
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Table 2.2 The Durie-Salmon staging system (Durie and Salmon, 1975) 
Stage Criteria Measured Myeloma Cell Mass 
I All of the following: < 0.6 cells x 
(Low cell mass) 
今 Hemoglobin value > 10 g/dL 
今 Serum calcium value normal or 
< 12 mg/dL 
今 Normal bone lesion (scale 0) 
or solitary bone plasmacytoma only 
今 Low monoclonal immunoglobulin 
production rate 
> IgG value < 5 g/dL; 
IgA value < 3 g/dL 
> Bence Jones protein < 4 g/ 24 h 
II Fitting neither stage I nor stage III <0.6-1.2 cells x 1 
(Intermediate cell mass) 
III One or more of the following: > 1.2 cells x 1 
(High cell mass) 
今 Hemoglobin value < 8.5 g/dL 
今 Serum calcium value normal or 
> 12 mg/dL 
� Advanced lytic bone lesions (scale 3) 
今 High monoclonal immunoglobulin 
production rates 
> IgG value > 7 g/dL; 
IgA value > 5 g/dL 
> Bence Jones > 12 g/ 24 h 
Subclassification 
A. Relatively normal renal function (serum creatinine value <2.0 mg/dL) 
B. Abnormal renal function (serum creatinine value > 2 mg/dL) 
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Table 2.3 The international staging system (Greipp et al, 2005) 
Stage Criteria 
I Serum p 2-microglobulin < 3.5 mg/L 
Serum albumin > 3.5 g/dL 
II Serum p 2-microglobulin < 3.5 mg/L 
Serum albumin < 3.5 g/dL 
or Serum p 2-microglobulin 3.5-5.5 mg/L 
III Serum (3 2-microglobulin > 3.5 mg/L 
2.1.7 Treatment 
The choice of therapy depends on the disease stage, clinical presentation, as well as the 
age and health of patient. Patients with MGUS or asymptomatic MM should not be 
started on therapy but monitored carefully only. In contrast, treatment should be 
immediately installed on those with symptoms or at threat for complications owing to 
MM (Ludwig et al, 2005). 
High-dose chemotherapy with autologous transplantation is the treatment of choice for 
newly diagnosed MM patients younger than 65 years old who are physiologically 
qualified for transplantation. All other patients are candidates for conventional 
(standard-dose) chemotherapy such as MP (melphalan, prednisone), VAD (vincristine, 
adriamycin, dexamethasone) or new drug thalidomide-based which can be used as single 
agent or in combination with MP, dexamethasone etc (Ludwig et al, 2005; Saunders, 
2005). Maintenance therapy has been provided for patients with remission with the use 
of thalidomide or steroids such as prednisone to prolong the duration of 
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remission(Kenealy and Prince, 2006). Recently, a new drug, bortzomib (proteasome 
inhibitor), has been approved for the use in patients with relapsed or refractory MM 
(Strobeck, 2007). 
2.1.8 Molecular Abnormality 
Almost all cases of MM are characterised by chromosomal abnormalities. Karyotypes 
from MM cells are usually very complex and can be subdivided into two cytogenetic 
categories: non-hyperdiploid (hypodiploid, pseudodiploid or near-tetraploid karyotypes) 
and hyperdiploid. The hyperdiploid subtype is usually associated with multiple trisomies 
involving chromosomes 3, 5, 7，9，11，15, 19 and 21 while non-hyperdiploid subtype 
involves monosomy 13 or 13ql4 deletion (Seidl and Kaufmann, 2003; Hideshima et al, 
2004). 
Besides, a majority of MM have an immunoglobulin heavy chain (JgH) translocation 
that involves one of many potential chromosomal partners (Hideshima et al.，2004). Five 
well-defined recurrent chromosomal partners are involved in IgH translocations in MM: 
l l q l 3 (cyclin Dl\ 6p21 {cyclin D3\ 4pl6 (fibroblast growth factor receptor 3 [FGFR3] 
and multiple myeloma SET domain [MMSET]\ 16q23 {c-mqf) and 20qll (c-myc). 
Together the combined prevalence of these five IgH transloation partners is about 40%, 
with approximately 15-20% llql3，5% 6p21，12% 4pl6, 5-10% 16q23 and <5% 20qll. 
Activating point mutations in N-RAS and K-RAS (or FGFR3 when there is a t(4;14) 
translocation) have been reported to occur in 10-40% of patients with MM at diagnosis 
and at even greater frequency in patients with advanced end-stage disease. Mutations 
and/or monoallelic deletion of tumor-suppressing p53 were found in few percentage of 
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early-Stage MM but up to 40% of advanced MM. Retinoblastoma {Rh) or pl8INK4c 
inactivation, loss of expression of platelet factor 4 (PF4), hypermethylation in 
death-associated protein kinase {DAPK), suppressor of cytokine signaling 1 {SOCSl) 
and cell-cycle regulators pl5 and pi6 have been reported in MM (Kuehl and Bergsagel, 
2002; Galm et al, 2003; Nakatsuka et al, 2003; Seidl et al, 2003; Chim et al., 2004; 
Mitsiades et al, 2004; Hideshima et al； 2004; Cheng et al, 2007). 
Bone marrow microenvironment plays an important role in MM pathogenesis. 
Specifically, adhesion of MM cells to extracellular matrix (ECM) proteins in BM 
confers cell adhesion-mediated drug resistance (CAM-DR), and binding of MM cells to 
bone marrow stromal cells (BMSC) triggers the transcription and secretion of a number 
of cytokines including interleukin-6 (IL-6), insulin-like growth factor 1 (IGF-1), 
vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-a, nuclear 
factor (NF)-KB and stromal cell-derived factor-1 (SDF-la), from BMSCs, which not 
only promotes growth, survival and migration of MM cells but also further leads to 
stromal independence of MM cells and therefore confers resistance to conventional 
chemotherapy (Hideshima et al, 2004; Saunders, 2005). 
2.2 DNA Microarray Analysis in MM 
Recently, the introduction of DNA microarray technology allows us to detect and 
monitor expression changes simultaneously in thousands of both known and 
uncharacterized genes in a comparative manner. Since cancer is a disease caused by the 
accumulation of genetic changes resulting from the expression of cancer-related genes, 
such as oncogenes or tumor suppressor genes, as well as genes involved in cell cycle 
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control, apoptosis, adhesion，DNA repair, and angiogenesis etc (Macgregor and Squire, 
2002)，microarray technology has been widely used in the past few years in cancer 
research. It has been applied to study cancer biology such as identifying tumor-specific 
molecular markers and cancer-related pathways. It also helped in cancer diagnosis and 
prognosis such as molecular classification of tumor subtypes, gene expression profiling 
of different stages of tumor progression, outcome prediction and treatment response 
biomarkers. Ultimately, improvement in clinical cancer therapeutics can be made. For 
example, cancer-related genes and pathways can serve as the target for new drug 
development. Also, with the development of drug response markers, sensitivity to a 
particular drug of cancer patients can be estimated and therefore hopefully tailored 
treatment will be made possible in the future (Macgregor and Squire, 2002; Mohr et aL, 
2002; Katoh, 2006; Parissenti et al, 2007; Pollack, 2007). 
The transcriptional behaviors of MM have been comprehensively assessed by DNA 
microarray, presenting as gene expression profiles. There are two main reasons which 
make MM a favorable target for gene expression studies (Margalit et aL, 2005; Tassone 
et aL, 2006). First，MM is a morphological homogeneous yet clinically heterogeneous 
disease, with dramatic differences in survival, which can range from several months to 
more than 10 years. Second, the genetic abnormalities underlying MM are very complex 
and variable, making it difficult to correlate between these molecular lesions and clinical 
outcome. Currently, measures of laboratory parameters can only account for no more 
than 20% of the outcome variability (Shaughnessy, 2003). Therefore, global gene 
expression profiling by DNA microarray provides a powerful and reliable tool for 
studying MM. 
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2.2.1 MM Pathogenesis 
By comparing the global gene expression profiles of malignant and normal samples 
generated by DNA microarray, a set of dysregulated genes in cancer can be identified as 
tumor-specific molecular markers as well as the altered pathways can be revealed, which 
not only provide more information in tumorigenesis, but also serve as the framework for 
new therapeutic targets (Macgregor and Squire, 2002; Pollack, 2007). 
Zhan et al was the first group to perform the comprehensive global gene expression 
profiling (GEP) of malignant BM plasma cells of newly diagnosed MM patients and 
contrast these expression patterns with those of normal plasma cells from healthy 
individuals. They found that MM plasma cells could be distinguished from normal 
plasma cells by their gene expression patterns. On the other hand, 120 novel candidate 
disease genes were able to best discriminate normal and malignant plasma cells with 50 
genes up-regulated and 70 down-regulated respectively in MM. Within these genes, 
many are involved in adhesion (e.g. ITGA2B, GP5, CD99, LAMCl), apoptosis (e.g. 
LCN2, ASM3A), cell cycle (e.g. CDK8, CDKN1A\ drug resistance (e.g. MVP\ growth 
arrest (e.g. PHB, QSCN6), oncogenesis (e.g. ABL, MYC, USP4, USF2, MLLT3\ 
signaling (e.g. TNFRSF7, S100A9, S100A12, PLA2G7, APOE, APOCl, HGF), and 
transcription (e.g. CEBPD, TCF7, HHEX, BTF3L2) (Zhan et al, 2002). 
Shortly after, another group, De Vos and Thykjaer, compared gene expression profiles 
of plasma cells from MM patients with nonmalignant plasma cells obtained by in vitro 
differentiation of peripheral blood B cells. They identified altered expression of cell 
cycle genes (e.g. cyclin Dl, C-MYC, CDC34, CUTLl), apoptosis genes (e.g. BCL2, BIK, 
IER3, HSP27), transduction genes (e.g. ABL, TYROS, RHOQ’ metabolism genes (e.g. 
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CBS, PFKM, GMPS), genes involved in metastasis or bone remodeling (e.g. SPARC). 
Noteworthy that this studies also offered new targets for therapy. The authors confirmed 
the overexpression of two genes in MM, ABL tyrosin kinase {ABL) and cystathionine 
beta synthase (CBS) which encode enzymes, highlighting their potential as therapeutic 
targets with specific anti-cancer drugs (ara-c on ABL; ST1571 on CBS) (De Vos and 
Thykjaer, 2002). 
Though comparison of GEP of MM and normal controls allows identification of genes 
modulated in MM, the genetically heterogeneous background of patients with MM and 
controls confounds comparison since gene expression is determined not only by 
environmental factors but also by the genetic background. To overcome this barrier, 
Munshi et al compared the GEP of plasma cells from a MM patient with that of plasma 
cells from a genetically identical twin. Highly expressed genes in MM cells included cell 
survival pathways genes (e.g. Caspase 8, MCLl, DAD1\ oncogenes/transcriptional 
factors (e.g. JUND, XBPl), stress response and ubiquitin/proteasome pathways-related 
genes and various ribosomal genes reflecting increased metabolic and translational 
activity, which provided more insights for the novel therapeutic strategies (Munshi et al, 
2004). 
In order to gain insights into the multi-step transformation process of normal plasma 
cells to MGUS and then to MM, Davies et al not only generated GEP of normal and 
MM plasma cells but also GEP of MGUS plasma cells. By contrasting the GEP of 
normal against MGUS and MGUS against MM, the global gene expression changes 
during these distinct disease stages were discovered. It was found that the differences 
between MGUS and MM were smaller than those between normal and MGUS or normal 
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and MM, indicating that most gene expression changes occur during the transformation 
of normal plasma cells to malignant MGUS plasma cells. Differentially expressed genes 
included oncogenes/tumor suppressor genes (e.g. LF4, RBI, disabled homolog 2), cell 
signaling genes (e.g. RAS family members, B-cell signaling and NFK-B genes), DNA 
binding and transcription-factor genes (e.g. XBPl, zinc finger proteins, forkhead box and 
ring finger proteins). Of particular importance, they discovered that a number of genes 
important in normal to MGUS transition including members of the Wingless {WNT) and 
Sonic pathways, which are developmental pathways not previously implicated in MM 
pathogenesis (Davies et al, 2003). More recently, a group performed the same study 
using a larger sample size of normal, MGUS and MM samples (Zhan et al, 2007). They 
identified 52 differentially expressed genes across normal, MGUS and MM plasma cells, 
which are involved in cell-cycle control, DNA synthesis, chromosome assembly，nuclear 
protein import, gene transcription, cell aging, cell signaling, metabolism, energy 
production, ion transport, reactive oxygen metabolism, drug resistance, and programmed 
cell death/apoptosis. These 52 genes separated MM patients into 2 groups: MGUS-like 
MM (MGUS-L MM) and non MGUS-like MM (non-MGUS-L MM). The MGUS-L 
signature in MGUS-L MM was found in strong association with the low-risk clinical and 
molecular features and superior survival in independent MM samples, further providing 
insight into the molecular mechanisms of plasma-cell dyscrasias. 
Another group, Magrangeas et al studied the MM tumorigenesis of different 
immunoglobulin (Ig) types and light chain types by comparing GEP of MM: IgG against 
IgA and K light chain against X light chain. It was found that genes associated with 
inhibition of differentiation and apoptosis were up-regulated while genes associated with 
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immune response, cell cycle control and apoptosis induction were down-regulated in 
IgA-MM, consistent with previous studies demonstrating that the IgA isotype was 
significantly associated with a shorter survival. Of note, several genes responsible for 
bone remodeling stimulation discriminated between IgK- and Ig^^-MM. One of 
overexpressed genes in IgK-MM, macrophage inflammatory protein (MIP)-lalpha 
(MIP-la\ showed strong positive correlation with active myeloma bone disease， 
providing possible explanation for the association between IgK-MM and bone 
destruction (Magrangeas et al, 2003). 
In order to identify molecular determinants of osteolytic lesions in MM, the GEP of 
plasma cells of MM patients with or without MRI-detected bone lesions at the time of 
diagnosis were compared (Tian et al, 2003). Only 4 genes were significantly 
overexpressed in MM patients with focal lesions. Within these 4 genes, only a gene， 
dickkopfl {DKK1\ encodes for a secreted factor that has been linked to the function of 
osteoblasts and was hence chosen for detailed research. Indeed, it was demonstrated in 
several assays that DKKl production by MM cells was associated with the formation of 
bone lesions. 
2.2.2 Molecular Classification of MM 
Histologically indistinguishable tumors often show significant differences in clinical 
behavior. This variability reflects the molecular heterogeneity of tumor. Since 
perturbation in the transcriptional program accounts greatly for the biologic diversity of 
tumor, GEP generated by DNA microarray can help to disclose genes whose expression 
could explain why these tumors respond differently to treatment and could be considered 
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ideal for molecular classification of cancer. Improvement in available tumor 
classification has great promise not only for assessing the biology of individual tumor 
entities but also for development of novel and individualized therapeutic approaches 
(Macgregor and Squire, 2002; Mohr et al, 2002; Pollack, 2007). 
The first molecular classification of MM was performed on plasma cells from 74 newly 
diagnosed MM patients (Zhan et al, 2002). Based on gene expression signatures, 4 MM 
subgroups (MMl, MM2, MM3 and MM4) were distinguished. The expression patterns 
of MMl were similar to normal plasma cells and MGUS, whereas MM4 was similar to 
MM cell lines. Clinical parameters linked to poor prognosis, abnormal cytogenetics, 
elevated serum p2-M levels, high creatinine and deletions of chromosome 13, were most 
prevalent in MM4. Also, genes involved in DNA replication/repair (e.g. TYMS, PRKDC, 
CDC6, MSH2) and cell cycle control (e.g. CKSl, UBE2V2, RANBPl) were found 
overexpressed in a comparison of MMl and MM4 subgroups. These results indicated 
that the gene expression profiles of MM discriminate 4 distinct clinical entities with 
MM4 likely representing the most high-risk clinical subgroups. Thus, knowledge of the 
molecular genetics of this particular subgroup provided information into its biology and 
possibly a rationale for appropriate subtype-specific therapeutic interventions. 
On the other hand, this group also compared the microarray profiling of tonsil B cells 
with plasma cells from tonsil and bone marrow (Zhan et al, 2003). Using the identified 
differentially expressed genes during the late B cell development, subsets of MM could 
be linked to that 3 normal cell types by clustering. These MM clusters were found to be 
consistent with the previously unsupervised gene expression defined subgroups, such 
that MM4, MM3 and MM2 have B cell-like, tonsil plasma cell-like, or bone marrow 
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plasma cell-like expression features, respectively. This study thus suggested that genes 
whose expression is linked to distinct transitions in late-stage B-cell differentiation can 
be used to classify MM. 
More recently, the same group performed molecular classification on plasma cells of 414 
newly diagnosed patients treated with high-dose melphalan-based tandem transplants 
with a training set consisted of 256 cases (Zhan et al, 2006). Seven disease subtypes 
(PR, LB，MS, HY，CD-I, CD-2 and MF) were validated that were strongly influenced by 
known genetic lesions, such as c-MAF- and MAFB-, CCNDl- and CCND3-, and 
MMSET'SLCtivaXing translocations and hyperdiploidy. Indicative of the deregulation of 
common pathways by gene orthologs, common gene signatures were observed in cases 
with c-MAF and MAFB activation (MF) and CCNDl and CCND3 activation, the latter 
consisting of 2 subgroups (CD-I, CD-2) with CD-2 subgroup characterized by 
expression of the early B-cell markers CD20 and PAX5. Hyperdiploid karyotype defined 
a distinct genetic entity (HY)with a good prognosis and largely devoid of common 
recurrent immunoglobulin-mediated translocation while a low incidence of focal bone 
disease distinguished one (LB). Increased expression of proliferation-associated genes 
distinguished another novel subgroup (PR)，which dominated at relapse compared with 
other subgroups, suggesting that this signature is linked to disease progression. Both the 
MMSET-spike (MS) and PR subgroups which exhibited a poor prognosis relative to the 
other groups were characterized by significant overexpression of genes mapping to 
chromosome Iq. Much noteworthy, regarding to the fact of the lack of progress in 
prolonging survival in patients with high-risk MM and the possibility that all MM will 
evolve to acquire an aggressive PR-like disease, this studies highlighted the 
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development of therapeutics that target the molecular pathways unique to high-risk 
disease, which can now elucidated through this new molecular classification of MM. 
Other than unsupervised molecular classification of MM, Agnelli et al，stratified GEP 
of plasma cells from 50 MM patients into five translocations/cyclins classes (TCI，TC2, 
TC3, TC4 and TC5) based on the presence of main translocations involving the IgH 
locus at 14q32 and cyclin D expression profiles (Hideshima et al.’ 2004) and identified 
the transcriptional fingerprints of each TC groups. TC2 group, which showed extra 
copies of the cyclin D1 locus and no IgH translocation, was characterized by 
overexpression of genes involved in protein biosynthesis, suggesting that this distinct 
transcriptional profile in TC2 patients could improve risk stratification and indicate 
novel therapeutic targets (Agnelli et al, 2005). Similarly, another group used the GEP to 
identify 5 recurrent translocations, specific trisomies and expression of cyclin D genes 
and divided 261 MM tumors into 8 groups. These groups were found to have different 
gene expression profiles and also significant differences in the prevalence of bone 
disease, frequency at relapse, and progression to extramedullary tumor (Bergsagel et al, 
2005). 
In addition, molecular classification of hyperdiploid type MM (H-MM) has been newly 
carried out by GEP (Chng et al, 2007). Within H-MM, four independently validated 
patient groups overexpressing non-overlapping sets of genes that form cognate 
pathways/networks that have potential biological importance in MM were identified. 
Notably, a prominent group (cluster 1) was characterized by high expression of cancer 
testis antigen and proliferation-associated genes. Tumors from these patients were more 
proliferative than tumors in other clusters and associated with shorter survival. Another 
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cluster (cluster 3) was characterized by genes involved in tumor necrosis factor/nuclear 
factor-kappaB signaling and antiapoptosis. These patients have better response to an 
anticancer drug, bortezomib, as compared with patients within other groups.. This 
analysis illustrated the heterogeneity within H-MM, suggesting that the signatures that 
defined these groups could provide a basis for tailoring treatment to individual patients. 
2.2.3 Anti-MM Drug Studies 
Obtaining further insights into the mechanism of action of anticancer drugs and the 
diverse pathways involved in drug resistance can eventually be valuable for design of 
more strategic treatments that are most appropriate for an individual tumor. Recently, 
DNA microarray technology has been used to dissect the anticancer drug pathways and 
resistance mechanisms using cancer cell line models (Macgregor and Squire, 2002; 
Mohr et al, 2002). 
In MM, microarray analysis has been applied for the study of the genetic changes 
underlying Doxorubicin resistance in MM cell lines in vitro and provided evidence that 
selection of doxombicin-resistant MM cells leads to changes in gene expression that 
reduce the apoptotic response to death-inducing stimuli (Watts et al, 2001). 
Moreover, the antitumor activity of Dexamthasone (Dex) in MM has been studied by 
contrasting GEP of MM cell line pre- and post-treatment (Chauhan et al, 2002). 
Particularly, transient activation of genes involved in DNA repair was followed by 
induction of apoptotic pathways and downregulation of genes promoting growth and 
survival. Moreover, mechanism of Dex-resistance has also been elucidated using 
Dex-sensitive and Dex-resistant cell line in the same study and data have been 
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confirmed in primary cells, demonstrating the clinical relevance of the findings. A 
further study by the same group showed that 2-methoxyestradiol (2ME2), an estrogenic 
derivative with anti-MM activity，was not only able to trigger an early repression of 
growth/survival-related genes and transient induction of genes known to trigger cell 
death and to regulate cell defense/repair machinery, but also modulate genes involved in 
Dex-resistance (Chauhan et al, 2003). 
The molecular mechanism of Realgar treatment for MM has also been elucidated. A 
number of differentially expressed genes were discovered between MM cell line before 
and after treatment. They were associated with a variety of cell life functions such as cell 
growth, cell-cell signaling, regulation of apoptosis and cell homeostasis. Several of these 
genes have been previously identified in relation to MM in published papers (Wang et 
al, 2006). 
Furthermore, a group studied the anti-MM activity of a novel drug, Raloxifene, a 
selective estrogen receptor modulator, on MM cell lines by DNA microarray. It was 
noteworthy that microarray analysis showed that raloxifene treatment decreased the 
expression of known NF-kappaB-regulated genes involved in myeloma cell survival and 
myeloma-induced bone lesions (e.g., C-MYC, MlPla, HGF, DUSP2) and induced the 
expression of a subset of genes regulating cellular cycle (e.g., p21, GADD, Cyclin G2\ 
offering the framework for future studies of selective estrogen receptor modulators 
therapy in MM (Olivier et al, 2006). 
The drug activity of a small-molecule VEGF receptor inhibitor, pazopanib in MM cells 
was also investigated by gene expression profiling (Podar et al, 2006). Results 
demonstrated that there was significant up-regulation of genes within the proapoptotic 
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gene ontology group and significant down-regulation of genes within the mitosis control 
pathway and gene products associated with MM pathogenesis including MMSET, MAF, 
and Syndecan 1 in pazopanib-treated MM cells. Other cancer-relevant genes and 
pathways were dysregulated, including down-regulation of survivin, MCLl, caveolin-1, 
IL-6 receptor, IGF-1 receptor，intergrins p7 and a4, and up-regulation of p21. 
In fact, DNA microarray technology has also been utilized to develop prognostic models 
in MM. Details will be further described in section 2.3.2. 
2.3 Cancer Treatment Response Prediction 
Despite considerable advances in cancer treatment, resistance to chemotherapeutic drugs 
continues to be a major obstacle in patient treatment and overall outcome (Macgregor 
and Squire, 2002), undoubtedly, the development of precise treatment response 
prediction prior therapy is beneficial to cancer patients and is urgently needed. 
2.3.1 MP Treatment 
In clinical practice, MP treatment is one of the major therapies for newly diagnosed MM 
patients. Yet, effective response predictors have not been identified. Lately, DNA 
microarray has been shown as a successful tool for chemotherapy response prediction in 
various cancers (Parissenti et al, 2007), suggesting its application in MP treatment 
response prediction in MM. 
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2.3.1.1 Melphalan 
Melphalan (Fig 2.2)，also known as Alkeran®, is a phenylalanine derivative of the 
nitrogen mustard class of chemotherapeutic agents and is primarily used to treat MM 
and ovarian cancer (Falco et al, 2007). It elicits its mechanism of action by the 
alkylation of DNA (Fig 2.3) (Hartley, 2002). It is capable of producing a number of 
different DNA adducts, the majority of which are monoadducts as a result of a single 
alkylation event. A small proportion of monoadducts then go on to form crosslinks as a 
result of a second alkylation. The formation of crosslinks between the 2 strands of DNA, 
interstrand crosslinking, is considered to be a critical event, and there is clear evidence 
that their formation and subsequent persistence correlates with in vitro cytotoxicity 
(O'Connor and Kohn, 1990; Simters et al, 1992). 
Both melphalan resistances after initial drug treatment {de novo drug resistance) and 
after chronic drug exposure (acquired drug resistance) have been observed in MM 
patients and several melphalan resistance mechanisms have been reported. 
vitro studies have identified several acquired melphalan resistance mechanisms, 
including defects in drug transport systems resulting in reduced drug uptake, increased 
binding to glutathione and increased repair of DNA interstrand crosslinks (Bellamy et al, 
1991; Dalton et al, 1992; Tew, 1994; Gottesman et al, 2002; Spanswick et al, 2002; 
Efferth et al, 2002). 
On the other hand, there are evidences suggesting that BM microenvironment inhibits 
drug-induced apoptosis and conveys a form of de novo drug resistance (CAM-DR) for 
MM cells. It has been demonstrated that BM component fibronectin (FN)-mediated 
adhesion via integrin VLA-4 (a4pl) confers a survival advantage for MM cells acutely 
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exposed to melphalan by inhibiting drug-induced apoptosis (Damiano et al, 1999; 
Damiano and Dalton, 2000). Later findings showed that MM cells adhered to FN exhibit 
a reversible resistance to melphalan-induced death by reducing melphalan-induced 
mitochondria depolarization and caspase activation (Hazlehurst et al, 2003). 
Furthermore, interaction of MM cells with bone marrow stroma was found to activate 
Notch-1 signaling in MM cells, resulting in protection of MM cells from 
melphalan-induced apoptosis (Nefedova et al, 2004). 
As mentioned in 2.2.3, DNA microarray has been utilized to investigate drug resistance 
mechanisms in MM. In fact, the genotypic profiles of de novo and acquired melphalan 
resistance have been compared in an isogenic MM cell line model with the use of DNA 
microarray (Hazlehurst et al, 2003). Results showed that a complex gene expression 
profile showing that genes involved in the Fanconi anemia (FA)/BRCA DNA repair 
pathway are increased in the MM 8226/LR cells (acquired melphalan resistance) 
compared with drug-sensitive 8226/S MM cells or MM cells adhered to FN (de novo 
melphalan resistance). On the other hand, gene expression changes associated with de 
novo resistance were significantly less complex compared with acquired resistance. 
Significant similarities in gene expression profiles were observed between cells with de 
novo and acquired melphalan resistance with the most striking similarity in gene 
expression profiles of up-regulation of molecules involved with cholesterol synthesis. 
Later in vitro study further demonstrated that enhanced interstrand cross-link (ICL) 
repair via the Fanconi anemia (FA)/BRCA pathway contributes to acquired drug 
resistance in melphalan-resistant myeloma cell lines, and disruption of this pathway 
reverses drug resistance (Chen et al, 2005). 
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Fig 2.2 Molecular structure of melphalan 
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2.3.1.2 Prednisone 
Prednisone, also called Deltasone® (Fig 2.4)，is a synthetic glucocorticoid (GC) and a 
prodrug that is converted by the liver into prednisolone, the active steroid drug. It has 
been used in combination therapy regimens for lymphomas and other blood cancers 
including MM. It is also useful in the management of complications such as 
chemotherapy-induced emesis, hypercalcemia ad increased intracranial pressure. 
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Till now, the precise mechanisms of prednisone toxicity in MM still remain unclear. Yet， 
there were extensive evidences suggested that GC could induce apoptosis in MM cells 
(Frankfurt and Rosen, 2004; Schmidt et al, 2004). The level of GC receptor (GR) 
expression in MM cells was found a critical determinant for GC sensitivity (Chauhan et 
al, 2002), suggesting the importance of the interaction of GC with GR in GC-induced 
apoptosis in MM. Besides, previous finding that overexpression of antiapoptotic BCL2 
family members attenuated GC-induced cell death in MM cell lines (Feinman et al, 
1999) suggested that GC might involve in direct regulation of death or survival genes in 
intrinsic apoptotic pathway. Also, interference with survival signaling through activation 
of the related adhesion focal tyrosine kinase (RAFTK/PYK2), a member of the focal 
adhesion kinase (FAK) subfamily, has been implicated in GC-induced apoptosis in MM 
(Chauhan et al, 1999), whereas interleukin-6 (IL-6) protected MM cells from 
GC-induced apoptosis and associated with RAFTK/PYK2 inactivation mediated by the 
protein-tyrosine phosphatase SHP2 (Chauhan et al, 2000), implying that GC might 
induce cell death by interfering with critical survival pathways in MM 
Similarly, the mechanisms of glucocorticoid resistance are not completely understood. 
GR transcriptional isoforais have been identified in GC-resistant MM cell lines and 
patients (Moalli et al” 1992; Moalli et al, 1993; Krett et al, 1995). Moreover, a recent 
study discovered that GRa is the predominant isoform in the GC-sensitive MM cells 
decreasing in expression in the early GC-resistant MM cells and virtually undetectable in 
late GC-resistant MM cells (Sanchez-Vega et al, 2006). These findings suggested that 
GR transcriptional isoforms, particularly, GRa, might be associated with development of 
GC resistance in MM. Besides, downregulation of BCL-2 or BCL-XL by antisense 
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oligonucleotides lead to sensitization of MM cell lines, and freshly isolated MM cells 
from patients (Liu et al., 2003), suggesting downstream mechanisms interfering with 
death or activating survival signals in GC resistance in MM. 
Fig 2.4 Molecular structure of prednisone 
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2.1 J. 3 MP Treatment Response Prediction in MM 
Despite the use of MP treatment on MM patients, only approximately 50% to 60% of 
patients respond to the treatment, resulting in a median response duration of 1 to 2 years 
and a median survival of about 3 to 4 years (Raaijmakers et al, 1998; Cavo et al, 2002). 
With no good biomarkers available for the precise prediction of patient's responsiveness 
to MP treatment, clinicians always face with the problem of not being able to identify 
the non-responder patients prior to starting the chemotherapy and not until the patients 
have been subjected to multiple course of toxic but ineffective chemotherapy. 
Several adverse prognostic factors, such as serum p2-M, plasma cell labeling index, 
cytogenetic abnormality etc. in MM were identified but their predictive value for 
treatment response are limited Examination of protein profiles in mammalian cancer 
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lines that display multidrug resistance led to the identification of P-glycoprotein (P-gp), 
expression of which is correlated with drug resistance (Kartner et al, 1983). This plasma 
membrane protein actively removes drugs from cell (Zaman et al, 1994). However, only 
a small portion of untreated MM expressed this protein and showed no value for 
predicting the patient's responsiveness to the treatment at that stage (Grogan et al, 1993; 
Comelissen et al, 1994). Similar to P-gp, multidrug resistance-related protein (MRP), 
acting as membrane drug transporter and potentially as a biomarker, did not confer 
resistance to melphalan (Izquierdo et al, 1996) and it has limited expression in MM 
(Rimsza et al., 1998). Moreover, B-cell lymphoma protein 2 (BCL-2) overexpression 
was found only associated with resistance to Dex, but not melphalan, in MM cells 
(Gazitt et al, 1998). 
By candidate gene approach, lung-resistance protein (LRP)，a major vault protein for 
mediating intracellular transport of melphalan was evaluated as a response predictor for 
MM patients. The result demonstrated that 52% Vs 18% of LRP negative and positive 
patients responded to the treatment at diagnosis (Raaijmakers et al, 1998). In addition, 
BCL2-like 1 (BCL-X) expression in MM was found correlated with the decreased 
response rate in patients treated with MP (Tu et al, 1998) whereas another studies 
showed the correlation between impaired melphalan uptake with down-regulation of 
CD98, a 丄-phenylalanine transporter, in a few MM patients (Harada et al, 2000). Also, 
overexpression of PDZ domain containing 1 (PDZKI) within the Iql2-q22 amplicon 
was reported likely to be associated with drug resistance phenotype, including 
melphalan resistance, in MM cells (Inoue et al, 2004). Another group reported that 
melphalan-resistance patients presented overexpression of c-MYC protein and higher 
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receptor levels of serum angiogenic factor, platelet-derived growth factor beta 
polypeptide (PDGF-BB), compared to minor responding patients (Greco et al, 2006). 
Moreover, up-regulated expression and activity of cyclooxygenase-2 (COX-2) in MM 
cells containing activating RAS mutations was suggested to enhance ability of MM cells 
to resist melphalan (Hoang et al, 2006). More recently, it was found that the expression 
of human apurinic/apyrimidinic endonuclease 1 (APEl) was higher in 
refractory/relapsed MM cells whereas APEl protein expression was positively correlated 
with the dose and action time of melphalan and silencing APEl expression led to 
enhanced cell sensitization to melphalan in MM cells (Yang et al, 2007). 
Yet, taken altogether, the predictive values of these markers are still narrow for clinical 
application. Furthermore, increasing the number of biomarkers analyzed will further 
increase the accuracy of drug response prediction (Salonga et al, 2000). Thus, searching 
for new biomarkers for drug response prediction are critical task of MM research. 
2.3.2 Cancer Prognosis using DNA Microarray 
Lately, investigators have been actively conducted researches in both solid tumors and 
malignancies to identify molecular signatures with prognostic value using DNA 
microarray technology. (Parissenti et al., 2007; Pollack, 2007; Quintieri et al, 2007). 
These studies identified sets of genes with their expressions correlated with 
chemosensitivity as response prediction biomarkers. Several cancer-specific outcome 
predictors and treatment response markers have been classified, shedding light into the 
patients' outcome prediction and also the selection of the best treatment option in 
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clinical practice, so that ultimately, individualized cancer therapy will be made possible 
in the near future (Kemming et al, 2006). 
In solid tumors, a lot of efforts have been done in breast cancers. Chang et al reported a 
gene expression pattern that could predict response or resistance to docetaxel in patients 
with breast cancer (Chang et al, 2003) whereas, multi-gene predictors of sensitivity to 
neoadjuvant paclitaxel, fluorouracil, doxorubicin, cyclophosphamide chemotherapy 
were identified in breast cancer with the use of DNA microarray (Ayers et al, 2004; 
Hess et al, 2006). Also, prediction of sensitivity of non-small cell lung cancers to 
anticancer drugs such as docetaxel, paclitaxel, irinotecan, cisplatin, gemcitabine, 
vinorelbine and gefitinib based on the expression profiles by DNA microarray also 
performed by different groups to identify several predictor genes (Kikuchi et al, 2003; 
Kakiuchi et al, 2004). Furthermore, some groups have employed gene expression 
profiling to find out a number of genes useful in prediction of different types of 
chemotherapy in other cancers, such as osteosarcoma (Man et al, 2005), ovarian cancer 
(Selvanayagam et al, 2004; Jazaeri et al, 2005), bladder cancer (Takata et al, 2005), 
colorectal cancer (Del Rio et al, 2007)，esophageal (Yoshida et al, 2003), gastric 
cancers (Kihara et al, 2001) etc. 
Treatment predictor genes have also been discovered in blood cancers. Genes that 
distinguish between responder and non-responder to tyrosine kinase inhibitor Gleevec 
(STI571) (Kaneta et al, 2002) and imatinib (Villuendas et al, 2006) in chronic myeloid 
leukemia; induction chemotherapy in adult acute myeloid leukemia (Okutsu et al, 2002; 
Heuser et al, 2005; Anensen et al, 2007) and childhood acute lymphoblasitc leukemia 
(Holleman et al, 2004; Cario et al, 2005) were identified. 
32 
Chapter 2 Literature Review 
In order to translate in clinical practice, these predictor genes should be validated their 
clinical usefulness either retrospectively or prospectively with the use of a simple, robust, 
conventional assay such as the quantitative reverse-transciptase polymerase chain 
reaction (RT-PCR) (Wadlow et al, 2005). Losses et al. used this strategy to identify and 
validate a gene-expression signature specific to diffuse large-B-cell lymphoma, 
composed of genes culled from multiple lymphoma DNA micorarray studies, that 
predicts the response to standard combination chemotherapy with cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP). Their six gene {LM02, BCL6, FNl, 
CCND2, CCL3, and BCL2\ PCR-based diagnostic test provided information that is 
independent of the International Prognostic Index and that added to it as a clinical 
measure of the likely treatment out in patients with diffuse large-B-cell lymphoma 
(Losses et al” 2004). Similarly, Ma et al. distilled complex microarray-based gene 
expression information from their studies into a 2-gene signature (H0XB13, ILl 7BR) 
associated with benefit from adjuvant tamoxifen treatment in early stage breast cancer, 
which was subsequently validated using RT-PCR assays in an independent cohort of 
patients (Ma et al, 2004). 
Similar as other cancers, DNA microarray has also been applied to develop prognostic 
models in MM. Shaughnessy et al aimed at developing clinically relevant risk-adapted 
prognostic models for MM using gene expression signatures. GEP of 221 newly 
diagnosed MM patients before entering a Phase III clinical trial (Total Therapy II) were 
performed (Harousseau et al,, 2004). Four discrete groups were segregated based on 
GEP. These groups were characterized by significant differences not only in genetic 
features, such as chromosome ploidy, trisomy 11，and 14q32 IgH translocation, but also 
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clinical parameters, such as event-free (EFS) and overall survival (OS). Further analysis 
of these distinct gene expression patterns lead to discovery of three genes，ras-related 
nuclear protein {RAN), zinc fingers and homeoboxes 2 {ZHX2) and regulator of 
chromosome condensation (RCCl) and BTB (POZ) domain containing protein 2 
{CHCIL) associated with rapid relapse. Patients with high RAN expression had 
increased risk of event while patients with high ZHX2 or CHCIL had decreased risk of 
event, highlighting the combination of RAN overexpression and loss of expression of 
ZXH2 and CHCIL for MM prognosis. 
This year, one group found that 70 genes, 30% mapping to chromosome 1 were linked to 
early disease-related death from GEP of plasma cells from 532 newly diagnosed MM 
patients treated on 2 separate protocols (Shaughnessy et al” 2007). Importantly, most 
upregulated genes mapped to chromosome Iq and downregulated genes mapped to 
chromosome Ip. This 70-gene model and a 17-gene subset were validated to be able 
predict outcome in independent MM patients, suggesting that altered transcriptional 
regulation of genes mapping to chromosome 1 could be used to identify high-risk 
disease. 
Much more recently, another group recruited 669 MM patients with relapsed myeloma 
before enrolling in clinical trials of proteasome inhibitor, Bortezomib, and aimed to 
develop predictive classifiers of response and survival with Bortezomib (Mulligan et al, 
2007). Pretreatment gene expression pattern and predictive classifiers related to NF-KB 
activity, cell adhesion, protein biosynthesis, mitochondrial function and cytokine were 
developed and shown to be significantly associated with outcome via testing on 
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independent data. Of note, the survival classifier was shown to improve on the risk 
stratification provided by the International Staging System. 
Until now, the classifiers identified seem promising. Yet，the predictive accuracy of these 
markers required of a clinical diagnostic for MM treatment has not yet been defined, 
further refinement is necessary before it can be considered for clinical use in predicting 
patient response. 
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Chapter 3 Materials and Methods 
3.1. Patient Specimens for Gene Expression Profiling and Quantitative 
Real-time PGR 
Bone marrow (BM) aspirates from 12 untreated Chinese MM patients at diagnosis and 3 
unrelated Chinese normal individuals were recruited for microarray analaysis. The 12 
MM patients were then subjected to same standard MP treatment protocol and classified 
as MP good responders (GR), poor responders (PR) or fair responders (FR) based on the 
percentage of drop of peripheral blood and bone marrow plasma cells and drop of Bence 
Jones proteins in 24-hour excretion, confirmed by two consecutive measurements taken 
at least 4 weeks apart without other evidence of progression following MP treatment 
(Table 3.1). Within the 12 MM samples, 6 were MP GR and 6 were MP PR. A further 
series of additional BM aspirates from 12 newly diagnosed Chinese MM patients were 
used for validation studies by real-time PGR. All clinical samples were obtained from 
Prince of Wales Hospital and the Pamela Youde Nethersole Eastern Hospital, Hong 
Kong SAR, from October 2003 to December 2006. All MM cases were examined and 
classified according to the Durie-Salmon staging system (Durie and Salmon, 1975). The 
BM samples were processed freshly for magnetic cell sorting. 
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Table 3.1 Definition of MP treatment response 
Drop of peripheral blood and Drop of Bence Jones protein 
MP treatment response 
bone marrow plasma cells in 24-hour excretion 
Good >80% >90% 
F ^ 50% - 80% 50% - 90% 
P ^ < 50% < 50% 
3.2. Magnetic Cell Sorting of CD138-positive Plasma Cells 
3.2.1 Density Gradient Centrifugation 
Mononuclear cells were isolated using Ficoll-paque gradient centrifugation. Briefly, BM 
aspirates were diluted with one volume of IX PBS and layered gently over two volumes 
of Ficoll-paque Plus (Amersham Biosciences, USA) into centrifugation tube. After 
centrifugation at 400xg for 30 minutes at room temperature (RT) without braking, 
mononuclear cells were collected from the interphase layer and washed twice with cell 
sorting buffer (PBS with 0.5 % BSA) at 1200 rpm for 10 minutes. 
3.2.2 Positive Selection of CD 13 8-positive Cells 
Mononuclear cells were suspended in 80p,l cell sorting buffer per 5x10^ total cells and 
labeled with 20}al CD 138 microbeads (Miltenyi Biotec，Bergisch Gladbach, Germany) 
for 15 minutes at 4 After incubation, cells were washed with 10 times the labeling 
volume of buffer by centrifugation at 300xg for 5 minutes to remove any non-binding 
microbeads. Cells were then resupsended in 1ml buffer. An MACS separation column 
(Miltenyi Biotec, Bergisch Gladbach, Germany) were placed on the magnetic MACS 
separator (Miltenyi Biotec, Bergisch Gladbach, Germany) and rinsed with 1ml buffer. 
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Cell suspensions were loaded into column and unlabeled cells were collected as negative 
fraction (CD138-negative cells) from the flow-through. After washing the column twice 
with buffer to remove any unlabeled cells, the column was removed from the separator 
and placed on a fresh eppendorf. Buffer was added to column and the retained 
CD138-positive cells were eluted using a plunger. The magnetic separation step was 
repeated one more time to further purify the eluted CD138-positive cells using another 
separation column. Finally, the retained cells were eluted as positive fraction 
(CD138-positive cells). The procedure for magnetic cell sorting was illustrated in Fig 3.1. 
The purity of plasma cells were assessed by morphological examination on cytospin 
slides with May-Griinwald-Giemsa stain. 
Fig 3.1 Magnetic cell sorting of CD138-positive plasma cells 
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3.3 Generation of Gene Expression Profiles 
CodeLink™ Human Whole Genome Bioarray System (Amersham Biosciences, USA) 
with 45,674 human unique genes was used for mRNA expression profiling of plasma 
cells from 12 MM patients and 3 normal individuals. 
3.3.1 RNA Extraction 
Total RNA of CD138-postive plasma cells were extracted by Trizol reagent (Invitrogen, 
USA) and then purified by RNeasy Mini Kit (Qiagen, Germany). Briefly, up to 1x10? 
cells were homogenized with 1ml Trizol to lyse the cells. The homogenized samples 
were then incubated at RT for 5 minutes. Then, 200fj,l chloroform (BDH Inc.，Canada) 
was added. The contents were mixed vigorously followed by centrifugation at 
12,000rpm for 15 minutes at 4°C to separate the mixture into two phases. The upper 
aqueous layer was collected followed by the addition of 500 \i\ isopropyl alcohol (BDH 
Inc., Canada). The mixture was mixed gently and incubated for 30 minutes at RT. After 
incubation, the mixture was centrifuged at 12000 rpm for 10 minutes at 4 The RNA 
pellet was then washed with 75 % ethanol, air dried and dissolved in nuclease-free water. 
Afterwards, 350|il GITC-containing lysis buffer RLT and 250|al 96-100% ethanol were 
added to inhibit any action of RNase and create conditions to promote selective binding 
of RNA to RNeasy silica-gel membrane respectively. The mixture were then applied to 
RNeasy mini column and centrifuged for 15 seconds at 10,000rpm at RT for RNA to 
bind on the membrane. Ethanol-added buffer RPE was added twice to the column to 
remove any contaminants from the membrane followed by centrifugation for 2 minutes 
at 10,000rpm at RT to dry the membrane. The total RNA was finally eluted in 
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RNase-free water by centrifugation for 1 minute at 10,000rpm at RT. 
3.3.2 RNA Assessment 
The total RNA was quantified by UV spectrophotometry (Pharmacia Biotech, USA) 
with absorbance at 260nin (A260). Only total RNA with A26o-A28o ratio between 1.8 and 
2.1 were subjected to bioanalyzer (eGene, USA) to assess RNA quality to ensure no 
degradation in the RNA sample i.e. with distinct large and small ribosomal RNA bands 
(rRNA 28S and 18S) but no additional bands between the two rRNA bands or below the 
18S band. Only qualified total RNA was subjected to microarray analysis. 
3.3.3 Synthesis and Purification of Double-strand cDNA 
Briefly, for each RNA sample, 2|_ig total RNA was incubated with working solution of 
bacterial control mRNAs and T7 oligo(dT) primer for 10 minutes in 70 °C thermo-cycler 
followed by centrifugation and chilling on ice immediately. First-strand buffer, dNTP 
mix, RNase inhibitor and Reverse transcriptase were then added into the reaction 
mixture and incubated for 2 hours in 42 °C thermo-cycler to synthesize the first-stranded 
cDNA. Afterwards, second-strand buffer, dNTP, DNA polymerase mix and RNase H 
were added into the first-strand cDNA reaction mixture and incubated at 16 °C for 2 
hours to synthesize the second-stranded cDNA. Then, G F X T m PCR DNA and Gel Band 
Purification Kit (GE Healthcare, UK) was used to purify the double-stranded cDNA. 
SOOjil capture buffer was added to the cDNA mixture and loaded into GFX column 
followed by centrifugation for 1 minute at 13,000rpm to recover cDNA on the 
membrane. The membrane was then washed by wash buffer to remove any impurities. 
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The double-stranded cDNA was then eluted using nuclease-free water and the cDNA 
solution were dried in a speedvac concentrator until 9\i\ cDNA solution was left. 
3.3.4 In vitro Transcription (IVT) and Recovery of Biotin-labeled cRNA 
To perform in vitro transcription, T7 reaction buffer, T7 enzyme mix, biotin-ll-UTP 
(PerkinElmer) and T7 ATP, GTP, CTP, and UTP solution were added to the 9|al cDNA 
solution and incubated for 14 hours in thero-cycler at 37 °C to synthesize biotin-labeled 
cRNA. Afterwards, RNeasy Mini Kit (Qiagen, USA) was used to recover cRNA. 350)j,l 
GITC-containing lysis buffer RLT and 250^1 100% ethanol were added to inhibit any 
action of RNase and promote selective binding of RNA to the membrane respectively. 
The mixture were then applied to RNeasy mini column and centrifuged for 1 minute at 
13，000rpm at RT for RNA to bind on the membrane. Ethanol-added buffer RPE was 
added twice to the column to remove any contaminants from the membrane followed by 
centrifagation for 2 minutes at 13,000rpm at RT to dry the membrane. 30)il 
nuclease-free water was used to elute cRNA after 10-minute incubation. Another 30|_L1 
nuclease-free water elusion was performed to obtain total 60)j,l cRNA. UV 
spectrophotometry was then used to assess cRNA quantification and quality as 
mentioned in 3.4.2. 
3.3.5 cRNA Fragmentation and Hybridization Reaction Mixture Preparation 
Briefly, for each sample, 15|j-g cRNA were incubated with fragmentation buffer in 
thermal-cycler at 94 °C for 20 miniiutes and then 0 °C for more than 5 minutes to 
fragment cRNA. Hybridization buffer component A and B were then added to the 
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fragmented cRNA and incubated at 90 °C water bath for 5 minutes to denature cRNA. 
The hybridization reaction mixture was then chilled on ice for 5 minutes and loaded into 
CodeLink™ Human Whole Genome Bioarray (Amersham Biosciences, USA) within 30 
minutes of denaturing cRNA. 
3.3.6 Hybridization 
The hybridization reaction mixture was slowly injected into the Flex chamber on the 
12-slide shaker tray through the array input port without using the blow-out feature of 
the pipette. The chamber ports were sealed with sealing strips and port sealing tools after 
loading the hybridization reaction mixture. The shaker tray was fixed onto the platform 
of shaker-incubator and hybridization was carried out at 37 °C for 20 hours with the 
shaker speed of 300rpm. 
3.3.7 Post-hybridization Wash 
After hybridization, the Flex chamber was removed from the bioarray by lifting the tab 
and the bioarray was placed into a slot of the bioarray rack. The bioarray rack was then 
transferred into the pre-warmed (46�C)，0.75X TNT buffer (0.75M Tris-HCl, pH7.6; 
0.1125M NaCl; 0.0375% Tween 20) -filled large reagent reservoir incubated at 46 °C 
water bath for exactly one hour to remove any unbound or non-specifically bound cRNA 
on the bioarray. 
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3.3.8 Detection with Streptavidin-dye Conjugate 
The bioarray rack was then placed into the small reagent reservoir filled with 0.02|_ig/|jl 
Cy5-streptavidin (GE Healthcare, UK) in filtered TNB buffer (O.IM Tris-HCl, pH7.6; 
O.lSMNaCl; 0.5% NEN blocking reagent (PerkinElmer, ) and incubated at RT for 30 
minutes to stain the biotin-labeled cRNA bound on the bioarray. The reservoir was 
covered with lid to prevent from photobleaching of the fluorophore. After 30-minute 
incubation, the bioarray rack was placed into a large reagent reservoir filled with IX 
TNT buffer (O.IM Tris-HCl, pH7.6; 0.15M NaCl; 0.05% Tween 20) and incubated at RT 
for 5 minutes to wash away any unbound or non-specifically bound Cy5-streptavidin on 
the bioarray. This washing step was repeated three times. Then the bioarray rack was 
placed into O.IX SSC/0.05% Tween 20 solution and incubated for 30 seconds with 
continuous agitation to apply a more stringent wash to remove or non-specifically bound 
Cy5-streptavidin. Afterwards, the bioarray was dried by centrifugation at 2000rpm for 3 
minutes at temperature more than 20 °C. The bioarray was then placed into a 
light-protected slide box and was ready to be scanned. 
3.3.9 Bioarray Scanning and Spot Signal Quantitation 
GenePix 4000B Array Scanner (Axon Instrument, USA) and GenePix Pro 4.1 software 
were used for bioarray scanning. The bioarray was scanned at wavelength 635nm with 
700V PMT voltage. The pixel size was 5|Lim and the focus position was 0|im. 
CodeLink Expression Analysis v4.0 software was used to exclude any spot in case of 
poor spot quality and to adjust the spot positions in the image in case of any 
mispositioning of the spot to recalculate the corresponding spot signal intensity. The 
43 
Chapter 3 Materials and Methods 
actual spot radius was determined for each spot on the bioarray through data extraction 
and spot signal area i.e. the number of pixels per spot (Fig 3.2, region A) was determined 
through automated computations. The basic spot mean signal intensity i.e. the sum of all 
pixel intensity values in the spot area divided by the number of pixels was then 
calculated. A local background region was defined as a concentric ring around the spot 
of several pixels in width (Fig 3.2, Region C) to calculate spot background median 
intensity i.e. the median signal of the pixels within the background ring C. To ensure that 
no spot signal bleeds into the defined background area, a concentric buffer area of 
several pixels was used to separate the spot signal area from the background area (Fig 
3.2，region B). The raw intensity of the spot was defined as spot mean signal intensity 
minus spot background median intensity. 
A control probe report was generated by the CodeLink Expression Analysis v4.0 
software to assess bioarray quality. Signal intensity of all positive controls should be 
excess the threshold value while signal intensity of all negative controls should be lower 
than the threshold value. 
Fig 3.2 Delineation of the spot regions 
A: Spot signal area 
� B : Background buffer for which pixels are excluded from 
- - A , . : - ’ … : j B C 
\ \ �v�: .. J j j the background computations 
\ Vli：^^^^^^ / 
C: Background area 
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3.4 Microarray Data Analysis 
3.4.1 Normalization and Filtering 
After background subtraction, median normalization and gene filtering were performed 
using BRB-Array Tools microarray analysis package. 
For median normalization, a reference array was automatically chosen by the program as 
the median array i.e. the array whose median log-intensity value is the median over all 
median log-intensity values for the complete set of arrays. Arrays were then normalized 
to the reference array, so that the difference in log-intensities between the array and 
reference array had median of zero over all the genes on the array. 
Gene filtering was carried out to screen out genes that were less informative. A gene was 
excluded when less than 20% of the expression data had at least a 1.5 fold change, from 
the gene's median value or more than 50% missing expression data. Only genes passed 
the filter were subjected to following analysis. 
3.4.2 Unsupervised Clustering Analysis 
In order to evaluate how the samples were grouped together according to the similarity 
of their gene expression profiles, two separate unsupervised clustering algorithms, 
hierarchical clustering and principal component analysis (PCA) were used. 
Hierarchical clustering was applied to (1) all 12 MM samples and 3 normal samples, as 
well as (2) MP GR and PR by comparing their expression of the filtered genes. Using 
BRB-Array Tools microarray analysis package, the log-intensities of the filtered genes 
were median centered. Clustering was run using one minus Pearson correlation 
coefficient as a similarity metric and average linkage clustering. The results of this 
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unsupervised analysis were visualized in dendrograms indicating the similarities 
between the samples. 
For PCA, data was log transformed and then processed with XLSTAT software on (1) 12 
MM samples and 3 normal samples, (2) MP GR and PR. Given the high computational 
task required for this analysis, the gene number was reduced by selecting the genes with 
at least two standard deviations among the all samples. The first three principal 
components were visualized in a three-dimensional graphic generated by 
XLSTAT-3Dplot software. 
3.4.3 Supervised Class Comparison Analysis 
By BRB-Array Tools microarray analysis package, two-sample t-statistics and 
Significance Analysis of Microarrays (SAM), were carried out between the pre-defined 
(1) MM and normal samples and, (2) MP GR and PR samples, for the identification of 
statistically differentially expressed genes. 
Parametric two-sample t-statistics were computed at a (1) more stringent statistical 
significance level (univariate p<0.001) between MM and normal samples, and (2) less 
stringent statistical significance level (univariate p<0.01) between MP GR and PR 
samples. Random univariate permutation of class labels (463 permutations) were 
computed separately on each filtered gene in F test between MP GR and PR samples to 
generate a global test p value (permutation p<0.01) for false negative elimination. As the 
number of normal samples (N=3) was small in the test between the MM and normal 
samples at stringent threshold p-value (p<0.001), permutation tests lacked power for 
establishing statistical significance and were not performed. 
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SAM analysis was performed on each filtered gene with the program-defaulted false 
discovery rate of 0.1 by running 100 permutations of class labels of (1) MM and normal 
samples in a higher confidence interval (90也 percentile confidence) and, (2) MP GR and 
PR samples in a lower confidence interval (80^ percentile confidence). 
Differentially expressed genes among (1) MM and normal samples and (2) MP GR and 
PR samples were pooled out by the combination of two-sample t statistics and SAM as 
candidate differentially expressed genes for validation by quantitative real-time PCR. 
3.5 Microarray Verification and Candidate Gene Validation 
3.5.1 RNA Extraction 
Total RNA from plasma cells of a further series of 12 MM patients were extracted as 
mentioned in 3.3.1. The quality and quantity of RNA were determined by measuring 
absorbance at 260/280mn with a UV spectrophotometer (Pharmacia Biotech, USA). 
3.5.2 Reverse Transcription PCR 
l|ig of total RNA from plasma cells of all 15 MM and normal clinical samples used in 
microarray studies and further series of 20 MM patients was used to synthesize first 
strand cDNA by using the MuLV reverse transcriptase (Applied Biosystems，USA). The 
total reaction volume was 20 |j,1 containing 50 units of MuLV reverse transcriptase, 50 
pmol random hexamer (Applied Biosystems, USA), 20 units RNase inhibitor (Applied 
Biosystems, USA), GeneAmp IX Buffer II, 1.5 mM MgCb, 200 \xM dNTP. The 
conditions for synthesis were: 22 °C for 25 minutes, 42 °C for 65 minutes and 92 °C for 
2 minutes. 
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3.5.3 Quantitative Real-time PGR 
Power SYBER Green real-time PGR (Applied Biosystems, USA) was performed by 
7300 Real Time Biosystem (Applied Biosystems, USA) on (1) plasma cell cDNA from 
all 15 MM and normal clinical samples used in microarray studies, and also a further 
series of plasma cell cDNA from 12 MM patients for UNC13B, RRAGD, SERPINFl and 
PINKl’ genes that were shown to be differentially expressed in the normal and MM 
groups in microarray experiments, and (2) plasma cell cDNA from 6 MP GR and 6 MP 
PR samples used in microarray analysis for CYB5D1, a gene that were shown to be 
differentially expressed in MP GR and PR groups in microarray experiments. Primer 
sequences (Invitrogen, USA) designed for intron/exon boundaries for UNCI3B, RRAGD, 
SERPINFl, PINK] and CYB5D1 were shown in table 3.2. Thermal cycling conditions 
were 10 minutes at 95 and 50 cycles at 95 °C for 1 minute and 60 °C for 1 minute 
(UNC13B, RRAGD, SERPINFl and PINKl) or 50 cycles at 9 5 � C for 30 seconds and 
63°C for 30 seconds {CYB5D1). To calculate copy numbers of target genes and the 
endogenous control, housekeeping GAPDH gene in experimental samples, absolute 
quantitation was employed by generating standard curves using known quantites of 
target and control genes amplified from peripheral blood cDNA of healthy donors. The 
relative expressions of the target genes were determined by the normalization with 
GAPDH, calculated as the target gene to GAPDH ratios. Student's t test was used as 
statistical analysis to compare target gene expression levels among groups. All 
experiments were performed in triplicates. 
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3.6 Predictive Value Calculation 
With low CYB5D1 gene expression (CYB5DI/GAPDH gene expression ratio < 1 0 ’ 
defined as positive test result, positive predictive value (PPV) and negative predictive 
value (NPV) were calculated using normalized CYB5D1 gene expression data from 
quantitative real-time PCR to examine the prognostic significance of CYB5D1 gene 
expression in MP treatment response prediction in MM patients. PPV was defined as the 
percent of MM patients that were observed to be MP GR out of the patients predicted to 
be MP GR by low CYB5D1 gene expression and NPV was defined as the percent of 
patients that were observed to be MP PR out of the patients without low CYB5D1 gene 
expression. Sensitivity and specificity of low CYB5D1 gene expression to predict MP 
GR were also calculated. 
3.7 Experimental Flow 
In this study, we employed DNA microarray as our platform to identify (1) differential 
gene expression using clinical samples from MM patients and normal healthy donors, 
and (2) differential gene expression using MM MP GR and PR. Fig 3.3 and Fig 3.4 















































































































































































































































































Chapter 3 Materials and Methods 
Fig 3.3 Experimental Flow of Part I: Gene Expression Profiling of MM 
BM from 12 MM patients BM from 3 healthy donors . , 
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Fig 3.4 Experimental Flow of Part II: Development of MP Treatment 
Response Biomarker in MM 
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Chapter 4 Results 
4.1 Gene Expression Profiling of Chinese MM 
In order to establish the gene expression profiles of Chinese MM, CD138-sorted 
plasma cells from 12 newly diagnosed Chinese MM patients and 3 unrelated normal 
healthy Chinese controls were subjected to DNA microarray studies. A representative 
processed microarray slide after the experiment was illustrated in Fig 4.1. 
4.1.1 Unsupervised Clustering Analysis 
Two different unsupervised clustering algorithms, hierarchical clustering and 
principal component analysis (PCA) were performed to determine whether the MM 
patients and normal controls were grouped together in accordance with the similarity 
of their gene expression profiles. 
4.1.1.1 Hierarchical Clustering 
Based on gene expression of 11586 filtered genes, hierarchical clustering of 12 MM 
samples and 3 normal controls using centered correlation and average linkage 
generated a dendrogram (Fig 4.2) with three major branches: one branch (green) 
contained all three normal groups and the other two branches (red) were comprised 
of all MM samples. Though the 12 MM samples could not be clustered into one 
single branch, this result suggested that gene expression profiling could differentiate 
MM from normal plasma cells. 
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4.1.1.2 Principal Component Analysis (PCA) 
By using genes with at least two standard deviations (2410 genes) among the 15 
samples, PCA was used as a second unsupervised method to classify the samples. 
The first three principal components allowed us to display the 15 samples in a space 
with three dimensions (Fig 4.3). This PCA method delineated two clusters: a MM 
cluster (represented as yellow balls) and a normal group cluster (represented as green 
balls). This result further supported that MM and normal plasma cells could 
distinguish each other by their gene expression profiles. On the other hand, as shown 
in Fig 4.3, green balls were clustered close to one another, indicating that the three 
normal group samples share very similar gene expression patterns, whereas the 
scattered yellow balls suggested that the gene expression patterns among the 12 MM 
samples were quite heterogeneous. 
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Fig 4.1 A representative processed microarray slide 
Each red spot shown in the figure indicated the Cy5-labeled signal, in which its signal 
intensity represented that gene expression level and was quantified for analysis. 
r 
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Fig 4.2 Dendrogram showing the hierarchical clustering of MM and normal 
control plasma cells (PCs) 
Hierarchical clustering was performed on 12 MM and 3 normal PCs using 11586 
genes. Centered correlation and average linkage were used. One branch (green) 
containing all three normal (N) groups and the two branches (red) of all MM samples 
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Fig 4.3 Principal component analysis (PCA) of MM and normal control 
plasma •cells (PCs) 
PCA was performed on 12 MM and 3 normal PCs using 2410 genes with at least two 
standard deviations among the 15 samples. The Fl , F2 and F3 axes represented the ‘ 
first, second and third components that accounted for the most of the variation across 
the data set. .Yellow and green colors represented MM and normal PCs respectively. 
Two clusters: a MM cluster and a normal group cluster were produced. 
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4.1.2 Identification of Statistically Differentially Expressed Genes 
To identify specific genes differentially expressed between MM and normal plasma 
cells, supervised class comparison was performed in which arrays were grouped 
according to their sample type and their mean expression levels were compared using 
two sample t-statistics and SAM analysis. 
4.1.2.1 Two-Sample t-statistics 
By taking a univariate pO.OOl, out of 11586 filtered genes, 447 genes were found to 
be differentially expressed between MM and normal plasma cells in which 351 genes 
and 96 genes were down-regulated and up-regulated in MM respectively. The 
heatmap showing the differentially expressed genes between MM and normal plasma 
cells identified by two-sample t-statistics was illustrated in Fig 4.4. 
4.1.2.2 Significance Analysis of Microarrays (SAM) 
With false discovery rate of 0.1 and 90^ percentile confidence, 818 differentially 
expressed genes between MM and normal plasma cells were identified, with 769 
genes down-regulated and 49 genes up-regulated in MM samples. Fig 4.5 showed the 
heatmap showing these differentially expressed genes between MM and normal 
plasma cells identified by SAM. 
In order to identify candidate genes for validation by quantitative real-time PCR, 
statistically differentially expressed genes among MM and normal samples, 
commonly recognized by both two-sample t statistics and SAM, were pooled out. In 
the end, 311 differentially expressed genes were identified, within which 281 genes 
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were down-regulated and 30 genes up-regulated in MM samples, as illustrated in the 
heatmap shown in Fig 4.6. 
A number of differentially expressed genes were found to be involved in apoptosis, 
cell proliferation, cell cycle regulation, angiogenesis, cell migration and cell adhesion 
(Table 4.1). In addition, part of differentially expressed genes, such as PTEN, WWOX, 
TNFRSF7, CD 19, have been found correlated with previous MM studies (Table 4.2). 
Not surprisingly, several down-regulated genes in MM plasma cells have been 
reported their involvement as tumor suppressors in various kinds of solid and blood 
cancer as shown in Table 4.3. 
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Fig 4.4 Heatmap showing the differentially expressed genes between MM and 
normal plasma cells (PCs) identified by two-sample t-statistics 
Red color represented up-regulation and green color represented down-regulation of 
that genes. 447 differentially expressed genes (351 down-regulated genes and 96 
up-regulated genes in MM) were found between MM and normal (N) PCs (p<0.001). 
MM N 
genes 
. H i l -
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Fig 4.5 Heatmap showing the differentially expressed genes between MM and 
normal plasma cells (PCs) identified by SAM 
Red color represented up-regulation and green color represented down-regulation of 
that genes. 818 differentially expressed genes (769 down-regulated genes and 49 
up-regulated genes in MM) were found between MM and normal (N) PCs with false 
discovery rate of 0.1 and 90^ percentile confidence. 
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Fig 4.6 Heatmap showing the differentially expressed genes between MM and 
norma通 plasma cells (PCs) identified by both two-sample t-statistics and SAM 
Red color represented up-regulation and green color represented down-regulation of 
that genes. 311 differentially expressed genes with 281 down-regulated genes and 30 
up-regulated genes in MM were found between MM and normal (N) PCs. 
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Table 4.1 Differentially expressed genes between MM and normal plasma 
cells (PCs) 
Gene symbol Gene Name Fold change * 
Apoptosis 
TNFRSF7 Tumor necrosis factor receptor superfamily member 7 -8.70 
HMGBl High-mobility group box 1 -2.67 
HlPl Huntingtin interacting protein 1 -2.95 
ERCC3 Excision repair cross-complementing rodent repair deficiency, complementation -2.41 
group 3 (xeroderma pigmentosum group B complementing) 
UNC13B Unc-13 homolog B (C. elegans) +4.90 
Cell proliferation 
PTEN Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) -5.52 
WWOX WW domain containing oxidoreductase -4.59 
PPARD Peroxisome proliferator-activated receptor delta -3.40 
VIPRl Vasoactive intestinal peptide receptor 1 -2.97 
Cell cycle regulation 
TFDPl Transcription factor Dp-1 -3.85 
CDC6 Cell division cycle 6 homolog (S. cerevisiae) -3.18 
UHRF2 Ubiquitin-like, containing PHD and RING finger domains, 2 +5.76 
Angiogenesis 
SERPINFl Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium -4.52 
derived factor), member 1 
AMOT Angiomotin -4.12 
Cell migration 
CD99 CD99 molecule -5.68 
GP9 Glycoprotein IX (platelet) -3.62 
ACTNl Actinin, alpha 1 -2.86 
GNA13 Guanine nucleotide binding protein (G protein), alpha 13 -2.59 
CD2AP CD2-associated protein +4.88 
Cell adhesion 
PCDHGC3 Protocadherin gamma subfamily C, 3 -2.48 
PCDHAC2 Protocadherin alpha subfamily C, 2 -2.43 
SlGLECll Sialic acid binding Ig-like lectin 11 -2.33 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 4 Results 
4.1.2.3 Microarray Verification 
In order to confirm the microarray analysis accurately reflected the patterns of gene 
expression, the gene expression of four differentially expressed genes, two 
up-regulated and two down-regulated candidate genes in MM, were examined by 
quantitative real-time PCR using the MM and normal samples used in microarray 
experiment. 
RRAGD {Ras-related GTP binding D) was found up-regulated by 8.8 folds 
(pO.OOOl) in MM in microarray experiment. The upregulation of RRAGD in MM 
was verified by real-time PCR, in which the relative RRAGD gene expression level 
(normalized to housekeeping GAPDH) was 6.1 folds higher in MM than normal 
plasma cells (p=0.001) (Fig 4.7, panel A). 
UNC13B {Unc-lS homolog B (C. elegans)) was overexpressed in MM by 4.9 folds 
(pcO.OOOl) in microarray experiment. By real-time PCR, its gene expression was 
found up-regulated in MM plasma cells by 4.7 folds (p=0.002) (Fig 4.7，panel B) 
SERPINFl {Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member I) was found down-regulated by 4.5 folds in MM 
(p<0.0001) by microarray. The relative gene expression levels of SERPINFl in MM 
were found 9.8 folds (p=0.0001) lower than that in normal plasma cells by real-time 
PCR (Fig 4.7，panel C). 
PINKl {PTEN induced putative kinase) was found down-regulated by 2.4 folds in 
MM (p<0.001) in microarray experiment. The downregulation of PINKl in MM was 
verified by real-time PCR, in which its relative gene expression level was 3.9 folds 
lower in MM than normal plasma cells (p=0.03) (Fig 4.7, panel D). 
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Fig 4.7 Verification of gene array expression levels in microarray samples 
Gene expression levels were validated in MM and normal plasma cells (PCs) using 
microarray samples by quantitative real-time PCR. (A) RRAGD expression was 
higher in MM PCs than normal PCs (p=0.001). (B) UNC13B expression was higher 
in MM PCs than normal PCs (p=0.002). (C) SERPINFl expression was lower in 
MM PCs than normal PCs (p=0.0001). (D) PINKl expression was lower in MM PCs 
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4.1.3 Validation of Candidate Genes 
To further ensure the altered gene expression of the four candidate genes {RRAGD, 
UNCJ3B, SERPINFl and PINKJ) in MM, a larger cohort of 12 independent MM 
plasma cell samples was used to investigate their expression patterns by quantitative 
real-time PCR. 
The gene expression of RRAGD was found up-regulated by 4.7 folds in MM (p=0.01) 
(Fig 4.8，panel A) while UNC13B was found overexpressed in MM by 11 folds 
(p=0.001) (Fig 4.8, panel B). For SERPINFl, its gene expression was 7.5 folds lower 
in MM (p=0.006) (Fig 4.8，panel C), whereas the gene expression of PINKl was 
down-regulated by 15.7 folds in MM (p=0.05) (Fig 4.8，panel D). 
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Fig 4.8 Validation of gene array expression levels in independent samples 
Gene expression levels were confirmed in MM and normal plasma cells (PCs) using 
12 independent MM samples by quantitative real-time PCR. (A) RRAGD expression 
was higher in MM PCs than normal PCs (p=0.01). (B) UNC13B expression was 
higher in MM PCs than normal PCs (p=0.01). (C) SERPINFl expression was lower 
in MM PCs than normal PCs (p=0.006). (D) PINKl expression was lower in MM 
PCs than normal PCs (p=0.05). 
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4.2 Development of MP Treatment Response Biomarker in MM 
In order to identify biomarkers to predict MP treatment outcome of MM patients 
prior to starting the chemotherapy, CD138-sorted plasma cells from 6 MP responders 
and 6 MP non-responders at diagnosis were subjected to DNA microarray studies. 
4.2.1 Unsupervised Clustering Analysis 
Two different unsupervised clustering algorithms, hierarchical clustering and PCA 
were performed to determine whether the MP responders and MP non-responders 
were-grouped together according to their gene expression profiles. 
4.2.1.1 Hierarchical Clustering 
Based on gene expression of 10302 filtered genes, hierarchical clustering of 6 MP 
good responders (GR) and 6 MP poor responders (PR) using centered correlation and 
average linkage generated a dendrogram (Fig 4.9) with two major branches: one 
branch (red) containing mainly MP GR (4 GR out of 6 samples) and the other (green) 
comprising mainly MP PR (4 PR out of 6 samples), suggesting MP GR and PR could 
not perfectly separate into two distinct groups based on their gene expression 
profiling. 
4.2.1.2 PCA 
By using genes with at least two standard deviations (380 genes) among the 12 
samples, PCA was used to classify the samples. The first three principal components 
allowed us to display the 12 samples in a three dimensional space (Fig 4.10). This 
PCA method delineated two clusters: a cluster mainly of MP GR (represented as 
yellow balls) with 4 GR out of 6 samples and a cluster mainly of MP PR (represented 
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as green balls) with 4 PR out of 6 samples. Similarly, this result correlated with the 
hierarchical clustering that 8 out of 12 samples showed correct classification based 
on their gene expression profiles. 
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Fig 4.9 Dendrogram showing the hierarchical clustering of MM MP good 
responder (GR) and poor responder (PR) plasma cells (PCs) 
Hierarchical clustering was performed on 6 MM MP GR PCs and 6 MM MP PR PCs 
using 10302 genes. Centered correlation and average linkage were used. One 
GR-dominating branch (red) containing 4 GR and the one PR-dominating branch 
(green) of 4 PR were formed, indicating gene expression profiling could not perfectly 
separate MP GR and PR. 
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Fig 4.10 Principal component analysis (PCA) of MP good responder (GR) and 
poor responders (PR) plasma cells (PCs) 
PCA was performed on 6 MP GR and PR PCs using 380 genes with at least two 
standard deviations among the 12 samples. The Fl , F2 and F3 axes represented the 
first, second and third components that accounted for the most of the variation across 
the data set. Yellow and green colors represented MP GR and PR PCs respectively. 
Two clusters: a GR-dominanting cluster and a PR-dominanting cluster were 
produced. 
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4.2.2 Identification of Statistically Differentially Expressed Genes 
To identify specific genes differentially expressed between MP GR and MP PR, 
supervised class comparison was performed in which arrays were grouped according 
to their sample type and their mean expression levels were compared using two 
sample t-statistics and SAM analysis. 
4.2.2J Two sample t-statistics 
By taking a permutation p<0.01, out of 10302 filtered genes, only 24 genes were 
found to be differentially expressed between MP GR and MP PR in which 9 genes 
and 15 genes were up-regulated and down-regulated in MP GR respectively. The 
heatmap showing the differentially expressed genes between MP GR and MP PR 
identified by two-sample t-statistics was illustrated in Fig 4.11. 
4.2.2.2 SAM 
Since no differentially expressed gene between MP GR and PR was identified by 
- SAM using false discovery rate of 0.1 and percentile confidence, a lower 
confidence interval, 80^ percentile confidence, was applied in SAM with false 
discovery rate of 0.1. Only one gene, CYB5D1 (cytochrome b5 domain containing 1)， 
was identified. 
Given that CYB5D1 was commonly recognized by both two-sample t statistics and 
SAM as the gene statistically differentially expressed in MP GR and PR, CYB5D1 
was chosen as the candidate genes for validation. 
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Fig 4.11 Heatmap showing the differentialty expressed genes between MP good 
responders (GR) and poor responders (PR) identified by two-sample t-statistics 
Red color represented up-regulation and green color represented down-regulation of 
that genes. 24 differentially expressed genes (9 up-regulated genes and 15 
down-regulated genes in MP GR) were found between MP GR and MP PR 
(permutation p<0.01). 
O C D O O O O Q - Q - C l q _ Q _ C L 
— NAME 


























Chapter 4 Results 
4.2.3 Verification of Candidate Gene CYB5D1 
In order to confirm that CYB5D1 was truly differentially expressed between MP GR 
and PR, the gene expression of CYB5D1 was examined by quantitative real-time 
PCR using the same MM samples in microarray experiment. 
CYB5D1 was overexpressed in MP PR by 3.3 folds (permutation p<0.002) in 
microarray experiment. By real-time PCR, its relative gene expression levels 
(normalized to housekeeping gene GAPDH) was found up-regulated in MP PR by 2 
folds (p=0.01) (Fig 4.12) 
Using normalized CYB5D1 gene expression data from quantitative real-time PCR, 
the positive predictive value (PPV) and the negative predictive value (NPV) of low 
CYB5D1 gene expression (indicated as red line in Fig 4.12) in MP treatment response 
prediction were found 100% and 66.7% respectively (Table 4.4)，with 100% 
specificity and 50% sensitivity. The 100% PPV highlighted the prognostic potential 
of low CYB5D1 gene expression in identifying MP GR. 
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Fig 4.12 Verification of CYB5D1 gene expression level in microarray samples 
Gene expression level of CYB5D1 was validated in MM MP good responders (GR) 
and poor responders (PR) using microarray samples by quantitative real-time PCR. 
CYB5D1 expression was statistically higher in MP GR than MP PR (p=0.02) by 2 
folds. The red line indicated the arbitrary cut-off of CYB5D1 gene expression 
{CYB5D1/GAPDH ratio of 10"^ ) for calculation of PPV and NPV. 
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Chapter 5 Discussion . 
Chapter 5 Discussion 
5.1 Global Gene Expression Profiling: DNA Microarray 
Although all cells have the same information contained in DNA, most of the genome 
is selectively repressed, and this adaptive property of multicellular organisms is 
governed by gene expression regulation. Thus much can be learned about cell 
function by global assessment of gene expression (Mohr et al, 2002). 
In the past, gene expression was assessed by transcript imaging limited to the 
reductionist way of gene-by-gene approaches, which helped to provide information 
on gene structure, function, and regulation to address biological questions (Mohr et 
al, 2002). However, gene expression changes and evokes hundreds of different gene 
products while suppressing hundreds of other genes in response to a cellular 
perturbation or even during normal resting conditions. Consequently, methods that 
enable large-scale gene expression studies are desired for gaining the global picture. 
With the advent of a more complete and annotated human genome from the Human 
Genome Project, DNA microarray technology has provided a high-throughput, rapid 
and parallel molecular biotechnique to detect the global gene expression patterns in a 
single assay (Quackenbush, 2001). 
Cancer is a disease caused by the accumulation of genetic changes resulting from the 
expression of cancer-related genes, such as oncogenes or tumor suppressor genes, 
involving in cell cycle control, apoptosis, adhesion, DNA repair，and angiogenesis 
etc (Macgregor and Squire, 2002). DNA microarray technology has been widely 
applied to study cancer biology in the past decades. Given that global study of gene 
expression in MM in our locality has been lacking, in the first part of this study, we 
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employed DNA microarray to establish gene expression profiles of Chinese MM and 
to identify potential genes related to MM development, so as to gain more insights 
into the MM molecular oncogenesis and contribute to MM diagnosis, prognosis and 
targets for novel therapeutics development. 
On the other hand, DNA microarray has been effectively used as a tool for predicting 
drug response prior treatment in various cancers by identifying genes whose 
expression correlated with chemosensitivity as response prediction biomarkers 
(Parissenti et al., 2007). Since only about half of MM patients response to MP 
(Melphalan, prednisone) treatment and there is no current markers for predicting MP 
treatment response in MM patients, in the second part of this study, we made use of 
DNA microarray to determine the molecular signatures of MP responders and 
non-responders, aiming at early identification of MP non-responders before the start 
of chemotherapy and providing them alternative treatments. 
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5.2 Microarray Data Normalization and Gene Filtering 
The hypothesis underlying microarray analysis is that the measured intensities for 
each arrayed gene represent its relative expression level. By comparing the measured 
expression levels between different states on a gene-by-gene basis, differential 
expression patterns can be identified. But before the levels can be compared 
appropriately, a number of transformations must be carried out on the data to adjust 
the measured intensities and to select genes that are significantly differentially 
expressed between classes of samples (Quackenbush, 2002). 
After executing background correction to remove the unspecific background 
intensities of the scanner images, normalization should be subsequently performed to 
adjust microarray data for effects that are due to variations in the assay rather than 
the biology in order to make unbiased and reliable comparisons from the arrays, 
since microarray data are subjected to multiple sources of variation which include the 
array manufacturing process, the preparation condition of the biological sample, the 
hybridization condition of the sample to the array, and the quantification of the spot 
intensities (Do and Choi, 2006; Verducci et al, 2006). 
There are many approaches to normalize microarray expression levels. The method 
we chosen in our study is median normalization in which the arrays are normalized 
to a reference array whose median log-intensity value is the median over all median 
log-intensity values for the complete set of arrays, so that the difference in 
log-intensities between the array and reference array had a median of zero over all 
the genes on the array. This is a kind of the commonly used global total intensity 
normalization which is applied globally to the entire data set and with the advantage 
of simplicity (Quackenbush, 2002; Gusnanto et al, 2007). Total intensity 
normalization data relies on the assumption that the quantity of initial mRNA is the 
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same for each sample. Furthermore, it is assumed that some genes are upregulated in 
the query sample relative to the control and that others are downregulated. For the 
hundreds or thousands of genes in the array, these changes should balance out so that 
the total quantity of RNA hybridizing to the array from each sample is the same. 
Consequently, the total integrated intensity computed for all the elements in the array 
should be the same for all samples. Under this assumption, a normalization factor can 
be calculated and used to re-scale the intensity for each gene in the array 
(Quackenbush, 2001). After normalization, individual hybridization intensities are 
adjusted to balance them appropriately that meaningful biological comparison can be 
made. 
On the other hand, not all genes detected by microarray are expected to be expressed 
at a biologically meaningful level. Generally only a small fraction of the expressed 
genes is expected to be differentially expressed. The inclusion of a large number of 
genes that are expressed at low levels will add noise to the analysis, introduce 
measurement bias and reduce the sensitivity in detecting differentially expressed 
genes. Identifying these genes in advance, therefore, might improve the detection of 
biologically meaningful differences in expression. As a result, gene filtering should 
be done. Various filtering approaches have been proposed in several studies, but 
presently there is no general consensus or guidance on how to filter microarray data 
prior to analysis (Gusnanto et al, 2007). 
In our study, gene filtering was carried out to screen out the genes when less than 
20% of the expression data had at least a 1.5 fold change from the gene's median 
value or more than 50% missing expression data. By eliminating the genes with less 
variability or missing values, the number of genes and thus the noise decreases, 
facilitating subsequent data analysis. 
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5.3 Microarray Data Analysis 
Lately, computational tools for microarray data analysis are rapidly evolving and no 
clear consensus exists as to the best method for revealing patterns of gene expression. 
Indeed, it is becoming increasingly clear that there might never be a 'best' approach 
and that the application of various techniques will allow different aspects of the data 
to be explored. Consequently, choosing the appropriate algorithms for analysis is a 
crucial element of the experimental design (Quackenbush, 2001). In general, there 
are two basic approaches to analyze microarray data, unsupervised method and 
supervised method (Pusztai et al, 2003). Unsupervised method refers that the 
samples are not pre-defined into known classes before data analysis, whereas 
supervised method assign samples to known classes prior analysis. 
- 5.3.1 Unsupervised Clustering Analysis 
In order to assess how the samples were grouped together based on the similarity of 
their gene expression patterns, unsupervised clustering of samples is usually 
performed. Various clustering algorithms exist and in our study, two different 
clustering methods, hierarchical clustering and principal component analysis (PCA) 
were carried out. 
5.3.1.1 Hierarchical Clustering 
Hierarchical clustering has the advantage that it is simple and the result can be easily 
visualized (Quackenbush, 2001). It has become one of the most widely used 
techniques for the analysis of gene-expression data. Hierarchical clustering is an 
agglomerative approach in which samples are joined to form groups, which are 
“ further joined until the process has been carried to completion, forming a single 
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hierarchical tree. 
The process of hierarchical clustering proceeds in a simple manner. First, the 
distance matrix is calculated for all of the samples to be clustered. Second, the 
distance matrix is searched for the two most similar samples to from clusters; in 
which initially each cluster consists of a single sample. Third, the two selected 
clusters are merged to produce a new cluster that contains at least two objects. Fourth, 
the distances are calculated between this new cluster and all other clusters. Last, 
steps 2 to 4 are repeated until all objects are in one cluster (Quackenbush, 2001). 
There are various hierarchical clustering algorithms that can be applied to microarray 
data analysis. These differ in the separation distance matrix and the linkage method 
chosen. In our study, we computed the hierarchical clustering using one minus 
Pearson correlation coefficient as a distance metric and average linkage. Distance 
metric defines the distance between two samples. Since Pearson correlation is a 
commonly used measure of similarity of two columns of numbers (Sherlock, 2000), 
and hence one minus Pearson correlation can be served as a distance metric. On the 
other hand, during hierarchical clustering, the algorithm computes distances between 
the growing clusters and the remaining members of the data set, including other 
clusters by different linkage method. The linkage method we used in our study is 
average linkage. With average linkage clustering, the distance between two clusters 
is taken as the average of the distances between all pairs of elements, one from the 
first cluster and one from the second. The two clusters with the lowest average 
distance are joined together to form a new cluster. Typically, average linkage 
clustering gives acceptable results for gene-expression data (Quackenbush, 2001). 
One potential problem with hierarchical clustering method is that if a bad assignment 
is made early in the process, it cannot be corrected (Quackenbush, 2001). In view of 
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this, another clustering algorithm, PCA, was also performed in our analysis. 
5.3.1.2 PCA 
One difficult issue for clustering samples is to decide which genes to be used. Ideally, 
all available information and hence all genes should be used. However, clustering 
relies on genes that have discriminatory power: i.e. show very different expression 
levels over the samples. It is a fact that some genes may have many missing values, 
imputing of which may have an undesired anti-discriminatory effect on clustering. 
Moreover, some genes correspond with many imprecise measurements. The latter 
may be coped with by introducing weighted clustering, which assigns relatively low 
weights to such genes. Principle components analysis (PCA) helps to fix this 
problem. A principle component summarizes the entire vector of gene expression 
values into one number. The first principal component does this such that the 
variability between the samples according to the value of this component is 
maximized; the second principal component maximizes the residual variability when 
accounted for the first principal component and so on. As a set they maximize the 
explained variability between samples. Hence, these principal components may have 
a lot of discriminatory power for clustering analysis and it is in effect a weighted 
analysis, assigning more weight to genes showing large differences over the samples 
(Armstrong and van de Wiel, 2004; Quackenbush., 2001). Furthermore, another 
advantage of PCA is that the first three principal components can be plotted in a 
three-dimensional graphics for easy visualization and interpretation. With these 
advantages, PCA was chosen for data analysis in our study. 
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5.3.2 Identification of Statistically Differentially Expressed Genes 
One of the goals of microarray application is to determine which genes are 
differentially expressed or any pathway show differential activation/inactivation 
across two kinds of tissue samples or samples under different physiological state or 
experimental conditions. By supervised method, gene expression between different 
defined classes can be compared to achieve this goal. 
In the early days, the simplest method for identification of differentially expressed 
genes is made using the fold-change selection (e.g. two-fold difference), but it is now 
not recommended as unreliable method as statistical variability is not taken into 
account, leading to two problems. First, genes with low expression levels yet large 
fold changes and high variability may be identified as differentially expressed. 
Second, genes that display small but reproducible (i.e., low variability) changes m 
gene expression may be missed (Pan, 2002; Verducci et al.’ 2006). Since then, many 
more sophisticated statistical methods have been proposed. The statistical test 
consists of two parts. The first is to construct a summary test statistic. The second is 
to determine the significance level or p-value associated with the test statistics. 
Though a wide range of approaches are available for computational analysis, but no 
general consensus exists as to standard for microarray data analysis protocol. In our 
studies, we found out differentially expressed genes by a combination of two 
statistical methods: two-sample t-statistics and Significance Analysis of Microarrays 
(SAM). 
In case of microarray analysis, traditional two-sample t-statistics tests for null 
hypothesis that the difference of the normalized intensities for each gene in test 
samples and control samples is equal to zero. It is a parametric test based on the 
assumption that normal distribution is hold for the observations (Pan, 2002). 
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Two-sample t-statistic is regarded better than a simple fold test since it does not only 
take into account how much a gene is differentially expressed, but also the 
consistency of the individual sample within each class used to assess the average 
differential expression level. This results in smaller fold changes being significant for 
genes whose expression levels are in high consistency within class, whereas large 
fold changes are considered non-significant if expression levels are in low 
consistency within class. 
By two-sample t-statistics, differentially expressed genes at the selected statistical 
significance level can be identified. In our analysis, we applied a more stringent 
statistical significance level (univariate p<0.001) for the comparison of MM and 
normal samples, and a less stringent statistical significance level (univariate p<0.01) 
for the comparison of MP GR and PR samples. Generally, univariate p-value less 
than 0.001 is more acceptable than 0.01 in identifying differentially expressed genes 
in microarray t-statistics as higher statistical significance level produces less false 
positive genes. Nevertheless, there is no standard rule for setting the maximum value 
of univariate p-value. Since hardly to identify genes differentially expressed in MP 
GR and PR samples when using univariate p<0.001, less significant univariate 
p<0,01 was used in this comparison. Given that there are enormous tested genes in 
the experiment, a number of false positive genes can also be picked out as 
differentially expressed genes, even with a high significance level in t-statistic. Thus, 
permutation test is usually used to estimate the null distribution empirically. For 
two-class comparisons, the class labels are randomly permuted to generate a new 
dataset, and the gene-wise statistics are re-computed. An empirical permutation 
p-value for a gene can be obtained by computing the proportion of realized permuted 
statistics greater than the observed one (Gusnanto et al, 2007). In fact, this global 
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test of whether the classes differ with regard to expression profiles will have better 
power for establishing that the expression profiles are different. Because a single 
global test is performed, obtaining a permutation p-value of less than 0.05 is 
sufficient to establish that the expression profiles are different. In our study, we have 
performed class permutation test in the comparison of MP GR and PR samples to 
identify differentially expressed gene, compensating the relative less stringent 
significance level (univariate p-value<0.01) used. In contrast, class permutation test 
was not carried out in comparison of MM and normal samples. It is because when 
the number of samples is small, the permutation tests lack power for establishing 
statistical significance at stringent threshold p-values. With small number of normal 
samples (N=3) and highly significance p-value (univariate pO.OOl)，it is not 
advisable perform permutation tests. 
Nevertheless, there are two main drawbacks for using two-sample t-statistics in 
identifying differentially expressed genes in microarray studies. The first one is that 
the model assumption of normal distribution of gene expression may not be achieved. 
The second one is that in microarray data analysis, standard r-statistic may not 
perform well in small samples (Gusnanto et al, 2007). 
Another statistical analysis performed on our microarray data was SAM, which is a 
non-paramatric method adapted specifically for microarrays. SAM is also robust and 
can be adopted in a broad range of experimental situations. It can identify genes with 
statistically significant changes in expression by assimilating a set of gene-specific t 
tests. Each gene is assigned a score on the basis of its change in gene expression 
relative to the standard deviation of repeated measurements for those genes, to avoid 
false positives due to under estimation of the gene variance. Genes with scores 
greater than an adjustable threshold are deemed potentially significant. For these 
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genes, SAM uses permutations of the repeated measurements to estimate the 
percentage of genes identified by chance, the false discovery rate (FDR) (Tusher et 
al, 2001). A valuable advantage of SAM is that it gives estimates of the FDR, which 
is the proportion of genes likely to have been identified by chance as being 
significant. Furthermore, SAM does not assume normal distribution of the data and it 
works effectively even with small sample size. SAM is a very interactive algorithm 
which allows users to set thresholds for controlling FDR. Since there is no standard 
FDR and confidence interval for SAM analysis, in our study, we performed SAM 
using the program-defaulted FDR of 0.1 by running 100 permutations of class labels 
of both comparisons of MM and normal samples, and MP GR and PR samples. 
Program-defaulted confidence interval (90^ ^ percentile confidence) was used in 
comparison of MM and normal samples. As no gene was identified in comparison of 
MP GR and PR samples when using 90^ percentile confidence, a lower confidence 
interval (80^ ^ percentile confidence) was then chosen. 
In order to identify genes with high possibility to be differentially expressed between 
the two groups, only the genes commonly pooled out by two-sample t-statistics and 
SAM were considered as candidate differentially expressed genes for later 
verification. 
5.4 Verification of Candidate Genes by Quantitative Real-time PCR 
Though microarray technology is a powerful tool for screening global gene 
expression profiles of biological samples, after data mining, results need to be 
validated with highly reliable biotechniques allowing for precise quantitation of 
transcriptional abundance of identified genes. Currently, quantitative real-time PCR 
technology, which is a sensitive, accurate and practical method for gene level 
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measurement, is considered by most experts the most appropriate method to confirm 
microarray-generated data (Provenzano and Mocellin, 2007). Therefore, we applied 
quantitative real-time PCR to verify the differential expression of candidate 
differentially expressed genes identified by microarray in our study. 
5.5 Gene Expression Profiling of Chinese MM 
CD138-sorted plasma cells from 12 newly diagnosed Chinese MM patients and 3 
unrelated healthy Chinese controls were subjected to DNA microarray studies. Using 
these cells, we have provided the first comprehensive global gene expression 
profiling of newly diagnosed MM patients and contrasted these expression patterns 
with those of normal plasma cells in our locality. 
5.5.1 Comparison of Gene Expression Patterns of MM and Normal Plasma Cells 
By both unsupervised hierarchical clustering (Fig 4.2) and principal component 
analysis (PCA) (Fig 4.3)，all MM plasma cells (PCs) can be separated from normal 
PCs, supporting that gene expression profiling could differentiate Chinese MM PCs 
from normal PCs. This finding correlates with previous microarray studies in MM in 
Western countries that MM and normal PCs could distinguish each other by their 
gene expression profiles (De Vos et al.’ 2002; Zhan et al.’ 2002; Davies et al, 2003). 
Furthermore, PCA (Fig 4.3) indicated that normal PCs were clustered closely 
together, demonstrating that the normal PCs share very similar gene expression 
patterns, whereas the MM PCs were clustered far apart, suggesting rather 
heterogeneous gene expression patterns among the MM PCs. 
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5.5.2 Differentially Expressed Genes between MM and Normal Plasma Cells 
A direct comparison of gene expression patterns in MM and normal PCs could also 
identify novel genes with highly significant differences that could represent the 
fundamental changes associated with the malignant transformation of PCs. Thus, we 
identified the statistically highly significant differentially expressed genes between 
MM and normal PCs by combination of supervised class comparison using 
two-sample t-statistics and Significance Analysis of Microarrays (SAM). 311 genes 
were found differentially expressed genes (Fig 4.6) and most genes were 
down-regulated in MM PCs compared with normal PCs (281 genes were 
down-regulated and 30 genes up-regulated in MM PCs). 
Among these genes, a number of them were found to be involved in apoptosis (Table 
4.1), including TNFRSF7 (8.70 folds downregulated), a tumor necrosis factor 
receptor (TNFR) which induces apoptosis (Prasad et al, 1997); HMGBl (2.67 folds 
downregulated), an anti-apoptotic oncoprotein which inhibits apoptosis when 
overexpressed (Brezniceanu et al, 2003); HIPl (2.95 folds downregulated), which 
has been reported contradictorily as both pro- and anti-apoptotic proteins (Hackam et 
al, 2000; Gervais et al, 2002; Rao et al, 2002; Rao et al, 2003); ERCC3 (2.41 folds 
regulated), an ATP-dependent DNA helicase which is involved in p5 3-mediated 
apoptosis (Wang et al” 1996; Spillare et al, 2006) and could induce apoptosis (Hu et 
al.’ 2006); UNCI SB (4.9 folds upregulated), diacylglycerol receptor which induces 
apoptosis (Song et al, 1999). 
Genes related to cell proliferation were also found differentially expressed in MM 
and normal plasma cells (Table 4.1). They are PTEN (5.52 folds downregulated), a 
phosphoinositide (PI) 3-phosphatase that can inhibit cellular proliferation, survival 
and growth by inactivating PI 3-kinase-dependent signaling (Leslie et al, 2004; 
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Chow and Baker, 2006); WWOX (4.59 folds downregulated), also known as fragile 
site FRA16D oxidoreductase {FOR) and behaves as suppressor of tumor growth in a 
variety of cancers such as breast, lung, prostate, prancreatic cancers etc. (Aqeilan and 
Croce, 2007); PPARD (3.4 folds downregulated), a ligand-activated transcription 
factor belonging to the nuclear hormone receptor superfamily in which its activation 
was reported to inhibit keratinocyte cell growth (Burdick et al, 2007) but induce 
proliferation of endothelial (Piqueras et al, 2007)，breast and prostate cancer cells 
(Stephen et al., 2004); VIPRl (2.97 downregulated), a receptor for vasoactive 
intestinal peptide (VIP) which inhibits proliferation of bone marrow progenitors 
(Rameshwar et al” 2002) but activates proliferation of human cord blood-derived 
hematopoetic progenitor cells (Kawakami et al, 2004), lymphoblastoma cells 
(Goursaud et al, 2005) and primitive neuroectodermal tumor cells (Fruhwald et al, 
1999). 
In addition, several differentially expressed genes involved in cell cycle regulation 
were identified (Table 4.1)，including TFDPl (3.85 folds downregulated), a 
transcription factor which binds to E2F transcription factor to form a heterodimeric 
transcription factor and regulate Gl-S cell cycle transition by controlling expression 
of genes required for growth and DNA synthesis (Cayirlioglu and Duronio, 2001; 
Ishida et al, 2005); CDC6 (3.18 folds downregulated)，which is required for G1 
origin licensing and S-phase DNA replication that is essential for DNA segregation 
during mitosis (Lau et al, 2006); UHRF2 (5.76 folds upregulated), a RING finger 
nuclear protein expressed in association with cell proliferation which induces G1 
arrest and associates with cyclin-dependent kinase 2 (CDK2) (Li et al, 2004). 
Two genes participated in angiogenesis were also differentially expressed in MM and 
normal plasma cells (Table 4.1). They are SERPINFl (4.52 folds downregulated), 
92 
Chapter 5 Discussion 
which has anti-angiogenic activity to inhibit cell migration (Ren et al, 2005); AMOT 
(4.12 folds downregulated), a receptor of an angiogenic inhibitor (angiostatin) which 
induces migration and tubule formation from endothelial cells (Troyanovsky et al, 
2001; Levchenko et al., 2004)，with its expression correlated with angiogenesis in 
human breast cancer (Jiang et al, 2006). In fact, some differentially expressed genes 
were also found involved in cell migration, including CD99 (5.68 folds 
downregulated), a leukocyte antigen which plays a role in transendothelial migration 
of human monocytes and lymphocytes (Lou et al, 2007; Bixel et al, 2007) and also 
gastric adenocarcinoma cell migration (Lee et al, 2007); GP9 (3.62 folds 
downregulated), a platelet glycoprotein which forms complex with glycoprotein IB 
to mediate endothelial cell migration (Lian et al” 1999; Lian et al, 2001); ACTNl 
(2.86 folds downregulated), an abundant actin crosslinking protein in which is 
involved in cell de-adhesion (Otey and Carpen, 2004) and its expression affects cell 
motility (Gluck and Ben-Ze'ev, 1994); GNA13 (2.59 folds downregulated), which 
was reported to stimulate cell migration (Radhika et al, 2004) and involved in 
endothelial cell migration (Offermanns et al, 1997; Simoncini et al, 2006); CD2AP 
(4.88 folds upregulated), which is involved in regulation of actin cytoskeleton 
(Kirsch et al, 1999; Bruck et al, 2006) and significantly contributes to cell 
migration in gastric epithelium (Mustonen et al, 2005). Moreover, several genes 
involved in cell adhesion were also found differentially expressed, including 
PCDHGC3 (2.48 folds downregulated) and PCDHAC2 (2.43 folds downregulated), 
which are cadherin-related adhesive molecules which play roles in function of 
specific cell-cell connections in brain (Reiss et al, 2006); SIGLECll (2.33 folds 
downregulated), a cell surface lectin involved in cell-cell interations in haemopoietic, 
immune and nervous systems (Crocker, 2002; Crocker et al, 2007). 
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•5.5.2.1 Common Differentially Expressed Genes with Previous Studies 
As expected, among the 311 differentially expressed genes, a number of them have 
been found altered expression in MM PCs or involvement in MM pathogenesis 
previously (Table 4.2)，confirming our results of microarray analysis. Of note, the 
gene coding for CD27, TNFRSF7, was found significantly under-expressed in MM 
PC (8.70 folds downregulated). It was also found down-regulated in MM by two 
Western groups using DNA microarray (Zhan et al, 2002; Davies et al, 2003), and 
Davies et al. validated its under-expression in MM in protein level by flow cytometry. 
CD27 is a member of the TNFR superfamily that provides costimulatory signals for 
T- and B-cell proliferation and B-cell immunoglobulin production and apoptosis 
(Prasad et al., 1997). Anti-CD27 significantly inhibits the induction of Blimp-1 and 
J-chain transcripts, which are turned on in cells committed to PC differentiation 
(Raman et al, 2000), suggesting that ligation of CD27 on B cells may prevent 
terminal differentiation. CD27 ligand (CD70) prevents apoptosis mediated by 
interleukin 10 (IL-10) and directs differentiation of CD27+ memory B cells toward 
PCs in cooperation with IL-10 (Agematsu et al, 1998). Thus, it is possible that the 
down-regulation of CD27 gene expression in MM may block an apoptotic program. 
Another down-regulated gene we identified, PTEN (5.52 folds downregulated), a 
cellular phosphatase involved in the regulation of phosphatidylinositol phosphates 
(PIP'S). It was a known tumor suppressor gene in MM (Ge and Rudikoff, 2000; Hyun 
et al, 2000; Choi et al” 2002). A mutation resulting in lack of expression of PTEN 
was identified in two MM cell lines. Loss of PTEN resulted in a failure to 
de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation leading 
to inhibition of apoptosis in MM cells. Furthermore, transfection of normal PTEN 
into MM cells inhibited in vivo tumour development, suggesting that PTEN 
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regulation may play an important role in MM development in a subset of patients. 
Yet，more recently, a group performed PTEN deletion and mutation analysis on MM 
patients and discovered that alterations of PTEN were uncommon in MM patients 
and tended to occur in advanced disease, suggesting that they are secondary, rather 
than primary, events in the pathogenesis of MM (Chang et al, 2006). WWOX was 
also found down-regulated (3.53 folds downregulated) in our MM samples. It has 
been shown to behave as a tumour-suppressor gene in vitro and translocations that 
inactivate a WWOX allele (16q23 translocations) occur in MM, but the other allele 
seems to be expressed normally and does not contain mutations (Bednarek et al” 
2001). In addition, variant 16q23 translocations that do not disrupt WWOX are seen, 
indicating that it does not have an important function in multiple myeloma (Chesi et 
al., 1998). However, a group recently carried out gene mapping and expression 
analysis of 16q loss of heterozygosity and identified WWOX as being important in 
determining clinical outcome in MM (Jenner et al., 2007). Phenotypic loss of B 
lymphocyte marker CD 19， which showed under-expression (4.59 folds 
downregulated) in our MM samples, was observed in almost all patients (97.5%, 
N=362) and constituted a marker of MM (Bataille et al, 2006) and normal PC 
retained some CD 19 expression (although weaker than that of B cells). As in primary 
myeloma cells, CD19 is very rarely expressed MM cell lines (1 out of 29). CD81, a 
member of tetraspanin family, was also found down-regulated (7.56 folds 
downregulated) in MM. Previous group showed that the promoter region of CD81 
was found hypermethylated in 4 MM cell lines and CD81 down-regulation was also 
determined in malignant plasma cells of MM patients (Drucker et al, 2006). Also, a 
group showed that CD81 overexpression had negative effects on cell adhesion, 
motility and invasion, supporting its role as tumor metastasis suppressors (Tohami et 
95 
Chapter 5 Discussion 
al, 2007). Other down-regulated genes common with Western studies included 
ACTNl (2.86 folds downregulated) which is involved in actin binding; CD99 (5.68 
folds downregulated) which is involved cell adhesion and migration; HLA-DPAl 
(10.87 folds downregulated) which is known to be involved in the early stage of 
B-cell development; PLA2G7 (4.60 folds downregulated) which functions in 
lipoprotein signaling; MCRl (2.50 folds downregulated) which mediates endocytosis; 
FCERIG (10.41 folds downregulated) which encodes a high affinity IgE receptor 
involved in allergic reactions; FABP4 (6-58 folds downregulated) which encodes a 
fatty acid binding protein and LILRBl (2.86 folds downregulated) which is involved 
in immunity. 
5.5.2.2 Potential Tumor Suppressor Genes in Differentially Expressed Genes 
Indeed, several down-regulated genes we identified have been reported as possible 
tumor suppressors in a variety of cancers, both solid tumors and blood malignancies 
(Table 4.3). F0XA2 (3.92 folds downregulated) was identified as novel tumor 
suppressor in lung cancer (Halmos et al, 2004) and was aberrantly methylated in 
human breast cancers (Miyamoto et al, 2005). LIMDl (2.58 folds downregulated) is 
encoded at chromosome 3p21.3 which is a region commonly deleted in many solid 
malignancies. It has been reported as a tumor-suppressor gene, with its protein 
product functionally interacted with phosphorylated retinoblastoma (Rb) protein and 
the loss of which promoted lung carcinogenesis (Sharp et al, 2004). The gene and 
protein expression pattern of RNASE 1 (6.49 folds downregulated) was similar to 
tumor suppressor genes and associated with the disease progression in gastric cancer， 
as its expression level was the highest in normal gastric epithelium, which was 
decreased in primary carcinoma, and further decreased in metastatic lymph nodes 
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(Wang et al, 2006). MLL5 (4.85 folds downregulated) was found frequently deleted 
element in cytogenetic aberrations of acute myeloid malignancies and its 
overexpression could inhibit cell cycle progression (Deng et al, 2004). 
Hypermethylation of PITX2 (4-85 folds downregulated) was frequently observed in 
acute myeloid leukemia (Toyota et al, 2001)，whereas HANDl (4-07 folds 
downregulated) was reported to be methylated in gastric (Kaneda et al, 2002), 
pancreatic (Hagihara et al, 2004) and ovarian (Imura et al, 2006) cell lines. 
Suppression of SELENBPl (5.92 folds downregulated) was found to be a late event 
in colorectal carcinogenesis and was associated with poor survival in colorectal 
cancer (Kim et al” 2006) and adenocarcinoma (Chen et al, 2004). It was also 
identified to be the most significantly down-regulated protein in ovarian cancer cells 
(Huang et al, 2006). CDC6 (3.86 folds downregulated), a cell cycle regulatory gene, 
was found down-regulated in prostate cancer (Robles et al, 2002) while reduced 
expression of RHCG (2,69 folds downregulated) was observed in oesophageal 
squamous cell carcinomas (Chen et al, 2002). Abnormal methylation of PACRG 
promoter was found associated with the downregulation of its gene expression in 
acute lymphoblastic leukemia and chronic myeloid leukemia, suggesting as a 
candidate tumor suppressor gene in hematological neoplasm (Agirre et al, 2006). 
Previous finding supported that overexpression of DDX6 (2.92 folds downregulated) 
in HeLa cells caused growth inhibition and cell cycle arrest at G2/M with 
down-regulation of c-myc expression (Matsui et al, 2006). Reduced expression of 
ERCC3 (2.41 folds downregulated) was found correlated with local tumor 
progression and poor prognosis in esophageal cancer (Terashita et al, 2004) and 
associated with a more than two-fold increased risk of squamous cell carcinoma of 
the head and neck (Cheng et a/.,2002). Also, it could inhibit the proliferation of 
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hepatoma cells (Hu et al, 2006). The involvement of SERPINFl (4.52 folds 
downregulated) in lung adenocarcinoma, colorectal carcinoma and ovarian caner and 
PINKl (2.44 folds downregulated) in ovarian cancer will be further discussed in 
5.5.2.4. 
5.5.2.3 Verified Differentially Expressed Genes 
To verify the microarray results, the gene expression levels of four differentially 
expressed genes with high significance level in the 12 MM and 3 normal PCs used in 
microarray experiment were studied by quantitative real-time PCR. They included 
two cancer-related down-regulated genes in MM, SERPINFl and PINKl, and two 
up-regulated genes in MM, RRAGD and UNCI3B. The expression of the four genes 
in MM and normal PCs showed same differential patterns as in microarray analysis 
(Fig 4.7)，supporting the credibility of microarray experiment. Moreover, in order to 
further confirm the differential expression of these four genes in a larger cohort, 12 
independent MM clinical samples were added to study their gene expression by 
real-time PCR. All four genes were validated in the independent samples (Fig 4.8). 
SERPINFl (13pl3.1) gene, also known as PEDE {pigment epithelium-derived 
factor), was validated to be underexpressed in MM PCs relative to normal PCs. It 
encodes a secreted 50-kDa glycoprotein first described as an ocular neurotrophic 
protein synthesized by fetal retinal pigment epithelial cells (Tombran-Tink and 
Johnson, 1989; Tombran-Tink et al, 1991). PEDF resembles, in sequence and 
structure, members of the serine protease inhibitor (serpin) family but lacks protease 
inhibitor activity itself (Cao et al” 1999). Subsequent studies demonstrated that it is 
widely expressed in most normal tissues. PEDF action appears to be cell specific. To 
neurons, PEDF is neurotrophic, promoting cell survival and differentiation (Taniwaki 
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et al, 1995; Houenou et al.’ 1999; Tombran-Tink and Barnstable, 2003). However, 
when endothelial cells are exposed to PEDF，PEDF behaves as a potent inhibitor of 
angiogenesis so that cell migration and proliferation are inhibited (Dawson et al, 
1999)，and cells undergo apoptosis (Volpert et al” 2002; Bouck, 2002). Although the 
specific functions of PEDF in cancer are not known, there is some evidence that 
PEDF could have inhibitory effects on tumor growth. First, its gene or protein 
expression was found in reduced many cancers, including melanoma, prostate, liver, 
non-small cell lung and ovarian cancers (Doll et al, 2003; Abe et al, 2004; Halin et 
al” 2004; Matsumoto et al, 2004; Zhang et al, 2006; Cheung et al, 2006). Second, 
PEDF has been reported to have a direct antitumor effect on melanoma (Abe et al, 
2004), osteosarcoma (Takenaka et al, 2005)，endometrial (Palmieri et al, 1999), 
prostate (Doll et al” 2003; Halin et al” 2004)，hepatocellular (Matsumoto et al, 2004) 
and ovarian (Cheung et al” 2006) cancer cells by inhibiting angiogenesis, cell growth, 
or cell migration. Third, in PECXF-knockout mice, vascular density is markedly 
increased, and epithelial cell hyperplasia is evident in the prostate and exocrine 
pancreas (Doll et al, 2003) and gene transfer of PEDE suppresses tumor 
vascularization and growth, while prolonging survival in murine models of thoracic 
malignancies (Mahtabifar et al, 2003). Finally, expression of PEDE gene was found 
to link with poorer clinical outcome in non-small cell lung cancer (Zhang et al, 2006) 
and ductal pancreatic adenocarcinoma (Uehara et al, 2004). Whether PEDE has any 
functional role in MM pathogenesis requires further investigation. 
PINKl {PTEN induced putative kinase 1) gene was found down-regulated in our 
MM PCs. PINKl gene (lp36) encodes a serine/threonine protein kinase located in 
mitorchrondria and linked to a recessive form of familial parkinsonism (Valente et al” 
2004). Though any functional involvement of PINKl in cancer development remains 
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unclear, previous studies indicated that a mutation at the nucleotide binding site 
within its kinase domain could render the protein unable to protect neuroblastoma 
cells from apoptosis, whereas its protein overexpression protects neuroblastoma cells 
(Valente et al, 2004; Petit et al, 2005). Also, PINKl could inhibit mitochondrial 
cytochrome c release, attenuating the general apoptosis machinery in neuroblastoma 
cells (Green and Kroemer, 2004; Petit et al, 2005). On the other hand, expression of 
PINKl gene was found to be decreased in ovarian tumors compared with 
corresponding normal tissues (Unoki and Nakamura, 2001), but increased in three 
mouse cancer cell lines with higher metastatic potential (Nakajima et al, 2003). 
More noteworthy, PINKl gene transcription was activated in PTEA -^mutant 
endometrial cancer cell lines after introduction of PTEN, a tumor suppressor in many 
human cancers (Unoki and Nakamura, 2001). Since PTEN has been known to be a 
tumor suppressor gene in MM (Ge and RudikofF, 2000; Hyun et al, 2000; Choi et al” 
2002) and its underexpression has been desmonstrated in our MM PCs, there may be 
high possibility that PINKl may participate in MM tumorigenesis. 
RRAGD {Ras-related GTP binding D) gene showed overexpression in MM in our 
study. RRAGD (6q 15-16) gene encodes a monomeric guanine nucleotide-binding 
protein (G protein) with a Ras-like GTPase superfamily domain (Sekiguchi et al, 
2001; Sekiguchi et al, 2004). Although RRAGD has not been reported any 
involvement in cancer development, it is well known that Ras-like small G proteins 
such as RAS, RAB, RHO, ARF, and RAN could function as molecular switches 
while also playing crucial roles in cell growth, differentiation, and protein traffic 
between different compartments within the cells (Exton et al, 1998) and some of 
them were identified to contribute to carcinogenesis, it is possible that RRAGD could 
play a part in MM development. 
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UNCI3B {Unc-13 homolog B (C. elegans)) (9pl2-ll) was validated to be 
up-regulated in MM. The encoded protein contains 3 C2 (protein kinase C conserved 
region 2) domains and a diacylglycerol-binding 1 CI (protein kinase C conserved 
region) domain. Previous studies discovered that UNC13B was upregulated by 
hyperglycemia and UNC13B could induce apoptosis, contributing to renal cell injury 
in hyperglycemia (Song et al, 1999). It also serves as an effector of RAB34, 
mediating lysosome-Golgi trafficking (Speight and Silverman, 2005) and regulates 
insulin exocytosis (Sheu et al, 2003). Moreover, UNCI3B gene mutations were 
reported to play a role in the development of familial haemophagocytic 
lymphohistiocytosis subtype 3 through a defective cytotoxic pathway (Yamamoto et 
al” 2004). Nevertheless, UNC13B has not been reported to be involved in any cancer 
studies. 
5.5.3 Future Studies 
In order to characterize the function of the four validated genes {SERPINFl, PINKl, 
RRAGD, UNCI SB) in MM pathogenesis, their protein expressions should be done. It 
can be achieved by either Western-blotting, immuno-histochemistry or flow 
cytometry. Once the correlations between their gene and protein expression have 
been verified, their role in MM tumorigenesis should be evaluated by transfection of 
SERPINFl or PINKl gene construct and of small interfering RNA (siRNA) of 
RRAGD or UNCI SB into MM cells. The Nucleofection® (Amaxa 
Biosystems,Geithersburg, MD) is a newly developed technology for efficient 
non-viral transfection of suspension cell types. The transfection of recombinant 
plasmid into human CD34+ hematopoietic cell has been successfully demonstrated 
(Takeda et al, 2006). The effect of re-expression of SERPINFl and PINKl and 
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silencing of RRAGD and UNC13B can be monitored by cell cycle analysis, 
apoptosis assay and cell proliferation assay. Moreover, to further confirm the possible 
significance of overexpression of RRAGD and UNC13B and underexpression of 
SERPINFl and PINKl in MM prognosis, a larger study with more detailed clinical 
outcomes of each patient is essential to understand their clinico-pathological role. 
Once their prognostic value is established, specific drug targeting them will offer 
superior treatment and potentially prevention for MM patients. 
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5.6 Development of MP Treatment Response Biomarker in MM 
CD138-sorted plasma cells from 6 MP good responders (GR) and 6 MP poor 
responders (PR) at diagnosis were subjected to DNA microarray experiment to 
identify biomarkers for prediction of MP treatment outcome of MM patient before 
the chemotherapy. 
5.6.1 Comparison of Gene Expression Patterns of MP Good Responders (GR) and 
Poor Responders (PR) 
By both unsupervised hierarchical clustering (Fig 4.9) and PCA (Fig 4.10), only 8 (4 
GR and 4 PR) out of 12 MM samples showed correct classification based on their 
gene expression patterns, indicating gene expression profiling could not perfectly 
separate MP GR and PR. This can be explained by two reasons. One explanation is 
due to the small sample size in this study. In several previous microarray studies 
comprising of a larger sample size in other cancers, gene expression profiles could 
not completely distinguish chemotherapy-sensitive and -resistant patients into 2 
distinct groups, with small number of patients showing incorrect classification. 
Though our samples were randomly selected, only 12 samples were included in our 
study, there may be possibility that a number of mismatch cases were selected by 
chance, leading to misclassification. Another explanation is that MP treatment 
response may be only predicted by the differential expression of small number of 
genes (biomarkers). Using the global gene expression patterns may add noises to 
classify GR and PR and produce wrong categorization. 
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5.6.2 Differentially Expressed Gene between MP GR and PR: CYB5D1 
To discover biomarkers to predict MP treatment response in MM patients, genes that 
show differential expression in MP GR and PR PCs were identified using a 
combination of supervised class comparison using two-sample t-statistics and 
Significance Analysis of Microarrays (SAM). Only one gene, cytochrome h5 domain 
containing 1 {CYB5D1) was found down-regulated in MP GR relative to MP PR. Its 
underexpression in MP GR was validated by quantitative real-time PGR (Fig 4.12). 
5.6.3 Possible Role of CYB5D1 in MP Resistance in MM Cells 
CYB5D1 (17pl3.1) gene encodes a novel protein with unknown function. Inferring 
from electronic annotation, it is proposed to have heme binding, iron ion binding and 
L-lactate dehydrogenase (cytochrome) activity. It is found that CYB5D1 contains a 
conserved domain, called cytochrome bs-like Heme/Steroid binding domain. Though 
CYB5D1 has not been illustrated to be involved in development or chemo-resistance 
in any cancer, the differential expression of CYB5D1 gene in MP GR and PR 
highlighted its potential role in MP resistance in MM. 
Cytochrome P450 (CYP) are monooxygenase enzymes with high expression levels 
in a variety of cancers, particularly solid tumors (McFadyen et al, 2004). They are 
key players in the metabolism of drugs and other xenobiotics, mostly catalysing 
oxidations of the substrate, but occasionally also reduction reactions, subsequently, 
they are able to inactivate many different cytotoxic drugs, rendering their 
cytotoxicity and effectiveness in cancer chemotherapy (Rodriguez-Antona and 
Ingelman-Sundberg, 2006). 
Previous studies reported that cytochrome bs could impose a positive modifier action 
of the CYP monooxygenase reaction (Reed and Hollenberg, 2003; Schenkman and 
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Jansson, 2003). To date, four distinct suggestions have been made to explain the 
mechanism this activation (Schenkman and Jansson, 2003).The first mechanism 
involves a direct input of an electron into the monooxygenase cycle, activating 
molecular oxygen in the rate-limiting step in the monooxygenase reaction. CYP all 
appear to be uncoupled to varying extents, releasing superoxide and hydrogen 
peroxide instead of oxidized substrate. A second mechanism suggests that 
cytochrome bs acts as a positive modifier of the monooxygenase by decreasing the 
extent of uncoupling of the monooxygenase reaction by faster input of the second 
electron via cytochrome bs, resulting in formation of more of the activated oxygen 
that reacts with substrate to form product. A third suggestion involves formation of a 
two-hemoprotein complex between cytochrome bs and CYP that allows acceptance 
of two electrons from NADPH-cytochrome P450 reductase. Uncomplexed 
cytochrome P450 accepts an electron from the reductase, dissociates from it, binds 
oxygen, and re-associates with the reductase to accept another electron. Complexing 
with cytochrome bs enhances the rate of formation of the active oxygen by obviating 
the need for two interactions with reductase. The fourth mechanism has cytochrome 
bs serving as an effector without a reduction-oxidation role in the monooxygenation 
reaction. This effector function may be to enhance the breakdown of the oxygenated 
hemoprotein to products or to facilitate flow of electrons through the system. 
Though both gene expression CYP and cytochrome bs were not found different 
between MP GR and PR, the facts that CYB5D1 gene expression was higher in MP 
PR relative to GR and CYB5D1 contains a cytochrome b5-like Heme/Steroid 
binding domain offers a possibility that CYB5D1 could stimulate CYP 
monooxygenase reaction as cytochrome bs and consequently, results in higher CYP 
monoxygenase activity and thus MP drug resistance in MP PR. Yet, this proposed 
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MP resistance mechanism requires further more investigation. 
5.6.4 Potential Clinical Application of CYB5D1 in MP Treatment Response 
Prediction in MM 
The gene expression of CYB5D1 was verified to be statistically up-regulated in MP 
PR relative to GR, suggesting its potential clinical use to predict MP treatment 
response prior therapy by CYB5D1 gene expression quantitation using real-time PCR. 
In order to examine the prognostic significance of CYB5D1 in predicting response of 
MP treatment, positive predictive value (PPV) and negative predictive value (NPV) 
of CYB5D1 gene expression were calculated as shown in Table 4.4 (Akobeng, 2007). 
Though low NPV (66.7%) indicated the poor performance of CYB5D1 gene 
expression to identify MP PR, the 100% PPV with 100% specificity highlighted the 
potential of low CYB5D1 gene expression for MP GR identification. Thus, we 
proposed that low CYB5D1 mRNA level can predict favorable response to MP 
treatment in MM patients and CYB5D1 can serve as a biomarker in MP treatment 
response prediction to identify MP GR. 
5.6.5 Future Studies 
The major limitation in our study is that a small sample size (6 MP GR and 6 MP PR) 
were employed for identifying of MP treatment response biomarkers. To further 
study, a larger sample size of MP GR and PR can be recruited for microarray analysis 
to identify any other biomarkers to distinguish the two groups of MM patients. 
Moreover, independent MP GR and PR clinical samples can be used to validate the 
differential expression between MP GR and PR of the candidate gene {CYB5D1). 
Furthermore, in order to study any functional role of CYB5D1 in MP resistance 
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mechanism, CYB5D1 gene and protein expression in MP-sensitive and MP resistant 
cell lines can be examined to find any correlation with the MP responses. Once the 
correlation is established, we can perform transfection of CYB5D1 gene transcript by 
Nudeofection® (Amaxa Biosystems,Geithersburg, MD) to MP-sensitive cell lines. 
The concentration of MP that is required for 50% inhibition in vitro ( I C 5 0 ) can be 
determined before and after transfection to study whether the CYB5D1 
overexpression can increase I C 5 0 in MM cells. 
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Chapter 6 Conclusion 
6.1 Gene Expression Profiling of Chinese MM 
This is the first study investigating the altered global gene expression in Chinese MM 
patients using DNA miroarray technology. Our results demonstrated the feasibility of 
gene expression profiling to distinguish Chinese MM plasma cells from normal 
plasma cells. 
Supervised analysis identified 281 and 30 candidate genes down-regulated and 
up-regulated in MM plasma cells. Among candidate genes, the down-regulation of 
SERPINFl and PINKl, as well as the up-regulation of RRAGD and UNCI SB were 
validated in 12 independent MM clinical samples, highlighting their potential roles in 
MM pathogenesis and tumor markers for MM patients. 
Nevertheless, the potential biological functions of their proteins in human MM 
tumorigenesis remain to be elucidated. Functional characterization on their biological 
functions may provide more information to understand MM pathogenesis. 
6.2 Development of MP Treatment Response Biomarker in MM 
In this part of study, we applied DNA microarray to identify biomarkers for 
predicting MP treatment response in MM patients prior to decision on treatment. Our 
results showed that eight out of twelve samples showed correct classification of MP 
treatment response based on their gene expression profiles. 
CYB5D1 {Cytochrome b5 domain containing I) was identified as the only gene 
differentially expressed in MP good and poor responders. The differential gene 
expression of CYB5D1 was validated statistically. The positive predictive value (PPV) 
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and negative predictive value (NPV) of low CYB5D1 gene expression in MP 
treatment response prediction were 100% and 66.7% respectively, highlighting the 
potential use of CYB5D1 gene expression in MP treatment response prediction for 
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